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5I Preface
It is our great pleasure to present the EMCDDA’s 21st annual analysis of Europe’s drug 
situation, our first as newly elected Director of the EMCDDA and as Chair of the agency’s 
Management Board. As in previous years, the European Drug Report 2016 offers a timely 
review of the latest trends and developments in the European drug situation, in the form of 
an integrated multimedia package. This report is unique in bringing together an up-to-date 
and top-level overview of drug use, drug problems and drug markets, and integrating this 
situational analysis with information on drug policies and practice. 
This year’s analysis once more highlights how Europe increasingly faces a more complex 
drug problem, in which stimulants, new psychoactive substances, misused medicines and 
problematic cannabis use all play a greater part. The report also reminds us that some of 
the problems of the past remain with us — even if the challenges they are now presenting 
for both policy and practice are changing. Europe’s opioids problem remains a central 
issue in the 2016 analysis, reflecting the significant impact these drugs still have on 
mortality and morbidity. We see now an increasingly complex relationship between use of 
heroin and synthetic opioids, accompanied by a worrying increase in overall estimates of 
opioid-related deaths. Treatment services in Europe are also now having to respond to the 
more complex health needs presented by an ageing cohort of heroin users, and 
policymakers wrestle with the difficult question of what constitutes the most appropriate 
long-term therapeutic goals for this group. At the same time, new heroin epidemics 
reported in other parts of the world remind us this is an area in which vigilance is required 
and ongoing surveillance remains essential. 
Our report is very much a collective endeavour, and we must thank here all those whose 
contributions made this report possible. As ever, the input from Reitox national focal points 
and national experts forms the basis for the analysis presented here. In addition, we have 
to acknowledge the input we have received from our institutional partners at European 
level; in particular the European Commission, Europol, the European Centre for Disease 
Prevention and Control and the European Medicines Agency. We are also pleased to note 
the inclusion in this year’s report of additional city-level information from European 
research networks, which complements national data in the areas of wastewater analysis 
and drug-related hospital emergencies and enriches our understanding of both drug 
consumption patterns and harms across Europe.
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Finally, we note this report is released at an important time for drug policy development, 
both in Europe and internationally. Within Europe, the achievements of the current drug 
action plan will be evaluated, and deliberations begun on the actions necessary to take 
forward the European drug strategy in the coming years. European countries have also 
been active in the international debates surrounding the UN General Assembly Special 
Session held in New York in April this year. The European position emphasised the value of 
a balanced and evidence-based approach grounded in a strong commitment for human 
rights. In our view, one of the reasons that Europe can speak with authority in this debate is 
the fact that there is a commitment to understanding the changing nature of the problems 
we face and to critically assessing what works. We are proud that this report and the work 
of the EMCDDA and its national partners continues to contribute to this understanding, 
and remain convinced that sound information is a prerequisite for sound policies and 
actions in this area. 
Laura d’Arrigo 
Chair, EMCDDA Management Board
Alexis Goosdeel 
Director, EMCDDA
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9I Introductory note and acknowledgements
This report is based on information provided to the EMCDDA by the EU Member States, the 
candidate country Turkey, and Norway in the form of a national reporting package. 
The purpose of the current report is to provide an overview and summary of the European 
drug situation and responses to it. The statistical data reported here relate to 2014 (or the 
last year available). Analysis of trends is based only on those countries providing sufficient 
data to describe changes over the period specified. Statistical significance is tested at the 
0.05 level, unless otherwise stated. The reader should also be aware that monitoring 
patterns and trends in a hidden and stigmatised behaviour like drug use is both practically 
and methodologically challenging. For this reason, multiple sources of data are used for 
the purposes of analysis in this report. Although considerable improvements can be noted, 
both nationally and in respect to what is possible to achieve in a European level analysis, 
the methodological difficulties in this area must be acknowledged. Caution is therefore 
required in interpretation, in particular when countries are compared on any single 
measure. Caveats and qualifications relating to the data are to be found in the online 
version of this report and in the Statistical Bulletin, where detailed information on 
methodology, qualifications on analysis and comments on the limitations in the 
information set available can be found. Information is also available on the methods and 
data used for European level estimates, where interpolation may be used. 
The EMCDDA would like to thank the following for their help in producing this report:
  the heads of the Reitox national focal points and their staff;
  the services and experts within each Member State that collected the raw data for this 
report;
  the members of the Management Board and the Scientific Committee of the EMCDDA;
  the European Parliament, the Council of the European Union — in particular its 
Horizontal Working Party on Drugs — and the European Commission;
  the European Centre for Disease Prevention and Control (ECDC), the European 
Medicines Agency (EMA) and Europol;
  the Pompidou Group of the Council of Europe, the United Nations Office on Drugs and 
Crime, the WHO Regional Office for Europe, Interpol, the World Customs Organisation, 
the European School Survey Project on Alcohol and Other Drugs (ESPAD), the Sewage 
Analysis Core Group Europe (SCORE), the European Drug Emergencies Network (Euro-
DEN) and the Swedish Council for Information on Alcohol and Other Drugs (CAN);
  the Translation Centre for the Bodies of the European Union, Missing Element Designers, 
Nigel Hawtin and Composiciones Rali.
Reitox national focal points
Reitox is the European information network on drugs and drug addiction. The 
network is comprised of national focal points in the EU Member States, the 
candidate country Turkey, Norway and at the European Commission. Under the 
responsibility of their governments, the focal points are the national authorities 
providing drug information to the EMCDDA. The contact details of the national focal 
points may be found on the EMCDDA website.
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Summary
Continued signs of resilience 
in the European drug market
The analysis presented here describes a 
European drug market that remains 
resilient, with some indicators for 
cannabis and stimulant drugs, in 
particular, now trending upwards. 
Overall, supply data suggest that the 
purity or potency of most illicit 
substances is high or increasing. The 
majority of recent survey data on 
prevalence also show modest increases 
in the estimated use of the more 
commonly consumed drugs. The drug 
marketplace is also more complex, with 
new substances available to consumers 
alongside more established drugs, 
signals that medicines are becoming 
more important, and with polydrug use 
patterns the norm among those 
experiencing drug problems. 
Interdiction efforts are challenged by 
the fact that production of cannabis, 
synthetic drugs and even some opioids 
and new psychoactive substances now 
takes place within Europe, near to 
consumer markets. Taken together this 
new analysis highlights the need for 
Europe’s drug policy agenda to 
embrace a broader and more 
complicated set of policy issues than 
has historically been the case.
 
I Resurgence of MDMA
The return of MDMA as a common stimulant of choice for 
young people is illustrative of some of the new challenges 
posed by the contemporary drug market. Innovation in 
sourcing precursors, new production techniques and 
online supply all appear to be driving a revival in a market 
now characterised by a diversity of products. High-dose 
powders, crystals and tablets with a range of logos, colours 
and shapes are available, with evidence of production to 
order and the use of sophisticated and targeted marketing. 
This may be a deliberate strategy by producers to improve 
perception of the drug after a lengthy period in which poor 
drug quality and adulteration had resulted in a decline in 
use. There are signals that this may be achieving some 
success, with indications that MDMA is becoming more 
popular, both with established stimulant consumers and 
with a new generation of young users. This points to the 
need for prevention and harm reduction responses to 
target a new population of users who may be using 
high-dose products but lack an understanding of the 
associated risks. 
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There is also a growing understanding of the health and 
social costs that can accrue from cannabis use. These are 
most pronounced among the more frequent and longer-
term users, with around 1 % of European adults estimated 
to be daily or near-daily cannabis users. For both resin and 
herbal cannabis, potency levels are high by historical 
standards and this is worrying, as it may increase the risks 
of users experiencing both acute and chronic health 
problems. The drug is also now responsible for the majority 
of new drug treatment entrants, although treatment entry 
data must be understood in the context of referral 
pathways and a wide definition of what constitutes care for 
this population. Policy responses in this area must also be 
mindful that in Europe, unlike in some parts of the world, 
cannabis is typically smoked with tobacco, making synergy 
between cannabis control and tobacco control policies 
important. 
I  Synthetic cannabinoids dominate seizures of new psychoactive substances 
An equally challenging issue for international and 
European drug policies is how to respond effectively to the 
dynamic and constantly changing market for new drugs. 
Very limited information is available on the use of new 
psychoactive substances, but the 50 000 reported seizures 
of these drugs in 2014 provide some insight into their 
relative availability. Synthetic cannabinoids account for 
over 60 % of these, and this drug class also features 
prominently in the 98 new substances detected for the 
first time in 2015 and reported to the EU Early Warning 
System for new psychoactive substances. Twenty-five of 
these were synthetic cannabinoids — drugs that act on the 
same brain receptors as THC, one of the main active 
compounds found in natural cannabis. From a health 
perspective, however, many synthetic cannabinoids are 
considerably more toxic, with mass poisonings and even 
deaths reported. The threat posed by these substances is 
highlighted by a warning issued by the EMCDDA in 
February 2016 about the synthetic cannabinoid MDMB-
CHMICA — a drug that had been associated with 13 
deaths and 23 non-fatal intoxications. This chemical was 
identified in more than 20 different smoking mixtures, and 
deaths or poisoning were identified in eight countries, and 
may have occurred in others. Consumers of these products 
would usually be ignorant of the chemicals they contain. 
I  New data highlight regional patterns in stimulant use and harms
This report suggests that identifying and responding to 
localised patterns of stimulant use and related harms 
needs to be given greater priority. Recent findings from 
wastewater analysis parallel seizure and survey data, all 
highlighting regional differences in stimulant consumption 
patterns across Europe. Cocaine use appears higher in 
western and southern European countries, while 
amphetamines are more prominent in northern and 
eastern Europe. Both cocaine and amphetamine have 
seen a medium-term increase in purity, with prices 
remaining largely stable. Stimulant-related problems are 
also becoming more visible. Concerns exist about an 
increased number of new amphetamines-related 
treatment demands in some countries, with nearly half of 
these new entrants reporting injecting. Injecting stimulant 
use has also been associated with recent outbreaks of HIV 
in some marginalised populations. Stimulant injecting 
associated with high levels of sexual risk-taking behaviours 
is also a growing concern. This has been reported among 
small groups of men who have sex with men in some 
European cities, pointing to a need for increased 
cooperation and a joined-up response from drug treatment 
and sexual health services.
I  Responding to cannabis remains a key challenge for European drug policies
Internationally, and in Europe, there is currently 
considerable public and political debate on the costs and 
benefits of different cannabis policy options. Data 
presented in this report inform this discussion by 
illustrating some of the complex issues that need to be 
taken into consideration. This topic is important, as levels 
of cannabis use overall do not appear to be falling and may 
even be starting to rise in some populations. Notably, of 
those countries that have produced a recent survey 
estimate (since 2013), a majority have reported increased 
use of this drug. 
New estimates show that cannabis accounts for the 
largest share in value of Europe’s illicit drug market. 
Cannabis production has become a major income 
generator for organised crime. Importation of cannabis 
from multiple source countries and increasing domestic 
production in Europe present a considerable challenge for 
law enforcement, with a resulting strain on already 
stretched police and customs resources. Cannabis 
offences, the bulk of which are for use or possession for 
personal use, also account for close to three-quarters of all 
drug-related offences. 
 Cannabis accounts for the  
 largest share in value of  
 Europe’s illicit drug market 
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AT A GLANCE — ESTIMATES OF DRUG USE IN THE EUROPEAN UNION
NB: For the complete set of data and information on the methodology see the accompanying online Statistical Bulletin.
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Afghanistan, increases in the size of heroin seizures and 
higher purity levels, all point to a possible increase in 
availability. There is currently, however, no strong evidence 
of increases in new heroin uptake, treatment entrance for 
heroin is declining or stable, and overdoses remain 
primarily a problem among older opioid users. 
Nonetheless, small increases have been observed in 
overdose deaths among younger groups in some countries, 
and this warrants closer attention.
I Use of synthetic opioids: cause of concern
The role of synthetic opioids and medicinal drugs also 
appears to be important in drug deaths in parts of Europe. 
Concerns exist about misused benzodiazepines and other 
medicines, diverted from therapeutic providers or obtained 
from unlicensed sources, but the role these drugs play in 
overdose deaths in Europe remains poorly understood. 
More data are available on synthetic opioids. Synthetic 
opioid products, mostly but not exclusively drugs used for 
substitution treatment, are more prominent in data on 
drug-related deaths in some countries, and there has also 
been an increase in treatment demand related to these 
substances. Given the severe public health problems 
experienced in North America and elsewhere with the 
misuse of opioid medicines, improved surveillance to 
detect any growing problems in this area at a European 
level is merited. In addition, and noted in the body of this 
report, regulatory frameworks and clinical guidelines can 
play a positive role in reducing the risk of diversion of 
medicines from appropriate therapeutic uses.
I  New pharmacological options for reducing drug harms
The coming years are likely to see the release of a range of 
new pharmacological options that could lead to increased 
opportunities for reducing some of the problems related to 
drug use. This report highlights two areas where new 
therapies and innovative delivery methods are being 
introduced. A number of EU countries provide the 
overdose-reversal drug naloxone to opioid users through 
community schemes or to drug users leaving prison with 
the aim of reducing overdose deaths. The wider 
implementation of take-home naloxone in Europe may be 
in prospect, with the development of nasally administered 
naloxone preparations, such as one recently given approval 
for pharmacy sale in the United States. New medicines are 
also becoming available that provide greater opportunities 
for treating hepatitis C virus infections among active drug 
injectors, including those in drug treatment settings. New 
therapies have a significant potential to provide health 
Adverse events are also associated with both uncontrolled 
stimulants and opioids reported to the Early Warning 
System. Responding effectively and rapidly to the sale of 
obscure chemicals, some of which subsequently are found 
to be highly toxic, poses one of the major policy challenges 
in this area. Young consumers may unwittingly be acting 
as human guinea pigs for substances for which the 
potential health risks are largely unknown. An example 
here is the synthetic cathinone alpha-PVP, which was 
risk-assessed in November 2015. This potent 
psychostimulant has been associated with almost 200 
acute intoxications and over 100 deaths in Europe. 
Producers of new psychoactive substances increasingly 
appear to be targeting the more chronic and problematic 
sectors of the drug market. Non-controlled synthetic 
opioids, such as members of the fentanyl family, are 
available, for example. These drugs can be particularly 
harmful. An example of note here is acetylfentanyl, which 
was subject to an EMCDDA–Europol joint report in 2015. 
New psychoactive substances have also been found in 
products marketed as replacements for medicines like 
benzodiazepines — medicines that when misused play a 
role in the drug problem in some countries.
I  Rises in overdose deaths: heroin back in the spotlight
This year’s analysis also highlights new concerns about 
rises in overdoses associated with heroin and other 
opioids. Heroin features prominently in data on fatal 
overdoses and is also the most common illicit drug 
reported in new European city-level data on hospital 
emergency presentations. The substances responsible for 
drug emergencies vary considerably between cities, with 
cannabis, cocaine and other stimulants also featuring 
prominently in some locations. Currently, data on acute 
drug problems are not collected systematically at a 
European level. The pilot city-level study suggests that 
routine monitoring in this area would be valuable to help 
better understand and track the impact of emerging drug 
problems.
A number of countries, mostly in the north of Europe, with 
long-established opioid problems report recent rises in 
opioid-related deaths. Understanding the drivers behind 
trends in this area, however, is complicated. Possible 
explanations include an increase in heroin availability, 
increasing purity, an ageing and more vulnerable user 
cohort and changing drug consumption patterns (including 
the use of synthetic opioids and medicines). Changes in 
reporting practice may also be important. Supply side data, 
including increased estimates of heroin production in 
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gain in the drugs area, but the challenge is to reduce 
barriers to their uptake and ensure sufficient resources are 
available to meet treatment needs.
I  New threats and opportunities provided by internet drug markets
An important new challenge for drug policy is how to 
respond to the internet’s role as both a communication 
medium and an emerging source of drug supply. Attention 
has focused primarily on the threat posed by darknet drug 
markets. It is also necessary to understand the growing 
role of surface websites, especially in respect to supply of 
counterfeit medicines and new psychoactive substances, 
and social media applications for peer-to-peer exchanges. 
Online platforms also provide possibilities for prevention, 
treatment and harm reduction activities, though these are 
often overlooked. 
The supply of drugs through online sources appears to be 
growing, albeit from a low base, and the potential for 
expansion of online drug supply appears considerable. 
Moreover, the rapid rate of change in this area, driven by 
increasing use of the internet, the deployment of new 
payment technologies, innovations in encryption and new 
options for the creation of distributed online marketplaces, 
makes it difficult for societal responses to keep pace. How 
best to respond to this growing dark cloud on the horizon 
and how best to exploit the opportunities that this medium 
offers for reducing drug problems are likely to represent 
questions of critical importance for the future European 
policy agenda. 
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In the global context, Europe is an 
important market for drugs, supported 
by both domestic production and drugs 
trafficked from other world regions. 
South America, West Asia and North 
Africa are important source areas for 
illicit drugs entering Europe, while China 
and India are source countries for new 
psychoactive substances. In addition, 
some drugs and precursors are 
transited through Europe en route to 
other continents. Europe is also a 
producing region for cannabis and 
synthetic drugs, with cannabis mostly 
produced for local consumption, while 
some of the synthetic drugs are 
manufactured for export to other parts 
of the world.
Monitoring drug markets, supply and laws
The analysis presented in this chapter draws on 
reported data on drug seizures, drug precursor 
seizures and stopped shipments, dismantled drug 
production facilities, drug law offences, retail drug 
prices, purity and potency. In some cases, the 
absence of seizure data from key countries makes 
the analysis of trends difficult. It should be noted that 
trends can be influenced by a range of factors, which 
include user habits and preferences, changes in 
production and trafficking, law enforcement activity 
levels and the effectiveness of interdiction measures. 
Full data sets and methodological notes can be 
found in the online Statistical Bulletin.
Also presented here are data on notifications and 
seizures of new psychoactive substances reported to 
the EU Early Warning System by the national 
partners of the EMCDDA and Europol. As this 
information is drawn from case reports rather than 
routine monitoring systems, seizure estimates 
represent a minimum. Data will be influenced by 
factors such as increasing awareness of these 
substances, their changing legal status and the 
reporting practices of law enforcement agencies. A 
full description of the EU Early Warning System can 
be found on the EMCDDA website under Action on 
new drugs.
Supporting information on European drug laws and 
policies is available on the EMCDDA website.
Chapter 1
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substances or falsified and counterfeit medicines. They 
can also operate on the deep web, through darknet 
markets or cryptomarkets, like AlphaBay or the defunct Silk 
Road. Cannabis products and MDMA are reported to be 
the illicit drugs most frequently offered for sale on darknet 
markets, alongside a range of medicines. 
A darknet market is an online sales platform or 
marketplace, supported by technologies that protect 
privacy, which brings together vendors, listing mostly illicit 
goods and services for sale. These markets have many 
similar characteristics to marketplaces such as eBay and 
Amazon, and customers can search and compare products 
and vendors. A range of strategies is used to conceal both 
transactions and the physical locations of servers. These 
include anonymisation services, such as Tor (the Onion 
Router), that hide a computer’s internet protocol (IP) 
address; decentralised and relatively untraceable 
cryptocurrencies, such as bitcoin and litecoin, for making 
payments; and encrypted communication between market 
participants. Reputation systems also play a role in 
regulating vendors on the markets. Recent developments 
include heightened security to prevent vendor scams, 
including the use of sophisticated escrow systems, and 
decentralisation of market platforms in response to threats 
from law enforcement. At present, these markets are 
believed to account for a small share of the trade in illicit 
drugs, and many of the transactions are at consumer level. 
However, the potential exists for further expansion of 
online drug trading.
Sizeable markets for cannabis, heroin and amphetamines 
have existed in many European countries since the 1970s 
and 1980s. Over time, other substances also established 
themselves — including MDMA in the 1990s and cocaine 
in the 2000s. The European market continues to evolve, 
with the last decade witnessing the emergence of a wide 
range of new psychoactive substances. Recent changes in 
the illicit drug market, largely linked to globalisation and 
new technology, include innovation in drug production and 
trafficking methods and the establishment of new 
trafficking routes. 
Measures aimed at preventing the supply of drugs involve 
actions by government and law enforcement agencies and 
often depend on international cooperation. At EU level, 
efforts are coordinated through the EU drugs strategy and 
action plans and the EU policy cycle for organised and 
serious crime. The approach that countries take is reflected 
in their national drug strategies and laws. Data on arrests 
and seizures are currently the best-documented indicators 
of drug supply disruption efforts.
I Drug markets: estimating financial value
Illicit drug markets are complex systems of production and 
distribution that generate large sums of money at different 
levels. A conservative estimate values the retail market for 
illicit drugs in the European Union at EUR 24.3 billion in 
2013 (likely range EUR 21 billion to EUR 31 billion). With 
an estimated retail value of EUR 9.3 billion (likely range 
EUR 8.4–12.9 billion), and responsible for about 38 % of 
the total, cannabis products account for the largest share 
of the illicit drug market in Europe. This is followed by 
heroin, estimated at EUR 6.8 billion (EUR 6.0–7.8 billion) 
(28 %), and cocaine at EUR 5.7 billion (EUR 4.5–7.0 billion) 
(24 %). Amphetamines occupy a smaller market share, 
estimated at EUR 1.8 billion (EUR 1.2–2.5 billion) (8 %), 
ahead of MDMA, at almost EUR 0.7 billion (EUR 0.61–0.72 
billion) (3 %). These estimates are based on very limited 
data, which has necessitated some broad assumptions, 
and hence must be viewed as initial minimum estimates 
that need revision in the future, as the information 
underpinning them is improved.
I New supply methods: online drug markets
While historically, illicit drug markets have been situated in 
physical locations, the last decade has seen the 
emergence of new internet technologies that have 
facilitated the development of online marketplaces. Drug 
markets can operate on the surface web, typically retailing 
non-controlled precursor chemicals, new psychoactive 
 Cannabis products account for  
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I Drug seizures: cannabis dominates
Over one million seizures of illicit drugs are reported 
annually in Europe. Most of these are small quantities of 
drugs confiscated from users, although multi-kilogram 
consignments seized from traffickers and producers 
account for a large proportion of the overall quantity of 
drugs seized. 
Cannabis is the most commonly seized drug, accounting 
for more than three quarters of seizures in Europe (78 %) 
(Figure 1.1), and reflecting its relatively high prevalence of 
use. Cocaine ranks second overall (9 %), followed by 
amphetamines (5 %), heroin (4 %) and MDMA (2 %). 
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FIGURE 1.1
Number of reported drug seizures, breakdown by drug, 2014
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In 2014, around 60 % of all seizures in the European Union 
were reported by just two countries, Spain and the United 
Kingdom, although considerable numbers of seizures were 
also reported by Belgium, Germany and Italy. It should also 
be noted that recent data on the number of seizures are 
not available for France and the Netherlands (countries 
that reported large numbers of seizures in the past) or for 
Finland and Poland. The absence of these data adds 
uncertainty to the analysis reported here. In addition, 
Turkey is an important country for drug seizures, with 
intercepted drugs intended for other countries, both in 
Europe and in the Middle East, as well as for local 
consumption.
I Cannabis: diverse products
Herbal cannabis (marijuana) and cannabis resin (hashish) 
are the two main cannabis products found on the 
European drugs market. Herbal cannabis consumed in 
Europe is both cultivated domestically and trafficked from 
external countries. The herbal cannabis produced in 
Europe is mostly cultivated indoors. Much of the cannabis 
resin is imported by sea or by air from Morocco. 
In 2014, 682 000 seizures of cannabis were reported in 
the European Union (453 000 of herbal cannabis, 229 000 
of cannabis resin). There were a further 33 000 seizures of 
cannabis plants. Nevertheless, the quantity of cannabis 
resin seized in the European Union is still much higher 
than that of herbal cannabis (574 tonnes versus 
139 tonnes). This is, in part, explained by the fact that 
cannabis resin is trafficked in volume over large distances 
and across national borders, making it more vulnerable to 
interdiction. In the analysis of the quantity of cannabis 
seized, a small number of countries are disproportionately 
important due to their location on major cannabis 
trafficking routes. Spain, for example, as a major point of 
entry for cannabis resin produced in Morocco, reported 
around two-thirds of the total quantity seized in Europe in 
2014 (Figure 1.2). In recent years, Turkey has been 
reporting larger quantities of herbal cannabis seized than 
any other European country. 
Seizures of other cannabis products are also reported in 
the European Union, including around 200 seizures of 
cannabis oil.
FIGURE 1.2
Seizures of cannabis resin and herbal cannabis, 2014 or most recent year
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Since 2009, the number of seizures of herbal cannabis in 
Europe has exceeded that of cannabis resin, and the gap 
has continued to widen (Figure 1.3). Over the same time, 
the quantity of herbal cannabis seized has continued to 
increase in the European Union. In the most recent data, 
the quantity of resin seized has increased in the European 
Union, while a sharp drop in the quantity of herbal 
cannabis seized is noted for Turkey.
Seizures of cannabis plants may be regarded as an 
indicator of the production of the drug within a country. 
Methodological problems mean that data on cannabis 
plant seizures must be considered with caution, 
nevertheless the number of plants seized more than 
doubled from 1.5 million in 2002 to 3.4 million in 2014.
Analysis of indexed trends among those countries 
reporting consistently shows a large increase in the 
potency (level of tetrahydrocannabinol, THC) of both 
herbal cannabis and cannabis resin between 2006 and 
2014. Drivers of this increasing potency may include the 
introduction of intensive production techniques within 
Europe and, more recently, the introduction of high 
potency plants in Morocco. 
FIGURE 1.3
Trends in number of cannabis seizures and quantity of cannabis seized: resin and herb
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route’. The first of these runs through Turkey, into Balkan 
countries (Bulgaria, Romania or Greece) and on to central, 
southern and western Europe. An offshoot to the Balkan 
route involving Syria and Iraq has emerged recently. The 
southern route seems to have gained importance in recent 
years. This sees heroin shipments from Iran and Pakistan 
entering Europe by air or sea, either directly or transiting 
through west, southern and east African countries. Other, 
currently less important routes include the ‘northern route’ 
and a new heroin route that appears to be developing 
through the southern Caucasus and across the Black Sea.
Following a decade of relative stability, markets in a 
number of European countries experienced reduced 
heroin availability in 2010/11. This is evident in heroin 
seizure data, which declined in the European Union from 
around 50 000 seizures in 2009 to 32 000 in 2014. The 
quantity of heroin seized within the EU showed a long-term 
decline, from 10 tonnes in 2002 to 5 tonnes in 2012, 
before increasing markedly to 8.9 tonnes in 2014. This 
reversal in trend is due to an increase in large seizures 
(above 100 kg), with several countries reporting record-
breaking heroin seizures in 2013 or 2014. In particular 
Greece and to a lesser extent Bulgaria reported large 
increases in quantities of heroin seized in the most recent 
data. Since 2003, Turkey has seized far more heroin than 
any EU country, seizing around 13 tonnes in 2014 
(Figure 1.4). 
I Opioids: market change? 
Heroin is the most common opioid on the European drug 
market. Imported heroin has historically been available in 
Europe in two forms: the more common is brown heroin 
(its chemical base form), originating mainly from 
Afghanistan. Far less common is white heroin (a salt form), 
which historically came from South-East Asia, but now 
may also be produced in Afghanistan or in neighbouring 
countries. Other opioids seized by law enforcement 
agencies in European countries in 2014 included opium 
and the medicines morphine, methadone, buprenorphine, 
tramadol and fentanyl. Some medicinal opioids may have 
been diverted from pharmaceutical supplies, while others 
are manufactured specifically for the illicit market. 
Afghanistan remains the world’s largest illicit producer of 
opium, and most heroin found in Europe is thought to be 
manufactured there or in neighbouring Iran or Pakistan. 
Opioid production in Europe has historically been limited 
to homemade poppy products produced in some eastern 
countries. However, the discovery of two laboratories 
converting morphine to heroin in Spain and one in the 
Czech Republic in 2013/14 indicates that heroin may also 
now be manufactured in Europe. 
Heroin enters Europe along four trafficking routes. The two 
most important are the ‘Balkan route’ and the ‘southern 
FIGURE 1.4
Number of heroin seizures and quantity seized: trends and 2014 or most recent year
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Among those countries reporting consistently, indexed 
trends suggest that heroin purity increased in Europe in 
2014. This, together with the rise in quantities seized and 
other developments, may signal a potential for the 
availability of this drug to increase.
I Europe’s stimulant market: geographic divide
A range of illicit stimulant drugs are available on the EU 
drug market, and there are regional differences with 
respect to which stimulant is most commonly seized 
(Figure 1.5). Largely these mirror the location of major 
production facilities as well as entry ports and trafficking 
routes. Cocaine, for example, is the most frequently seized 
stimulant in many western and southern countries, closely 
reflecting the locations through which the drug enters 
Europe. Amphetamine seizures are predominant in 
northern and central Europe, with methamphetamine the 
most commonly seized stimulant in the Czech Republic, 
Slovakia, Latvia and Lithuania. MDMA is the most 
commonly seized stimulant drug in Romania and Turkey.
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Most frequent stimulant seized in Europe, 2014 or most recent data
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I  Precursor chemicals: non-scheduled substances increasingly used
Precursor chemicals are essential for the manufacture of 
synthetic stimulants and other drugs. Their availability has 
a large impact on the market as well as the production 
methods used in illicit laboratories. As many have 
legitimate uses, EU regulations schedule certain 
chemicals, and trade in these is closely monitored. 
Producers of synthetic drugs seek to minimise the impact 
of controls by using non-scheduled chemicals to produce 
precursors. This approach, however, may also increase the 
risk of detection, as more chemicals are required and more 
waste is produced. 
Data from EU Member States on seizures and stopped 
shipments of drug precursors confirm the continued use of 
both scheduled and non-scheduled substances for the 
production of illicit drugs in the European Union, in 
particular for amphetamines and MDMA (Table 1.1). In 
2014, seizures of the BMK pre-precursor APAAN (alpha-
phenylacetoacetonitrile) amounted to 6 062 kg, down from 
48 802 kg in 2013. This dramatic reduction probably 
reflects the scheduling of this substance under EU 
legislation in December 2013. However, continued 
availability of MDMA on the market coupled with declining 
seizures of the MDMA precursor safrole, from 13 837 litres 
in 2013 to zero in 2014, suggest that alternative precursors 
are being used. Seizures of non-scheduled MDMA pre-
precursors, notably PMK glycidate, increased in 2014. 
I Cocaine: market stabilisation
In Europe, cocaine is available in two forms, the most 
common is cocaine powder (a hydrochloride salt, HCl) and 
less commonly available is crack cocaine, a smokeable 
(free base) form of the drug. Cocaine is produced from the 
leaves of the coca bush. The drug is produced almost 
exclusively in Bolivia, Colombia and Peru, and is 
transported to Europe by both air and sea routes. The 
range of methods used to transport cocaine to Europe is 
particularly diverse. It includes air couriers on commercial 
flights, commercial air freight, fast parcels and postal 
services, and private aircraft. By sea, cocaine can be 
smuggled in large consignments using private yachts and 
maritime containers. Together, Spain, Belgium, the 
Netherlands (based on 2012 data), France and Italy 
account for 84 % of the estimated 61.6 tonnes seized in 
2014 (Figure 1.6). 
In 2014, around 78 000 seizures of cocaine were reported 
in the European Union. The situation has remained 
relatively stable since 2010, although both the number of 
seizures and the quantity seized are at levels considerably 
lower than in the peak years (see Figure 1.6). While Spain 
continues to be the country seizing the most cocaine, there 
are signs of the ongoing diversification of trafficking routes 
into Europe, with seizures of the drug recently reported in 
ports on the eastern Mediterranean, Baltic and Black Seas. 
Overall, indexed trends suggest that the increase in the 
purity of cocaine seen in recent years has now levelled off.
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FIGURE 1.6
Number of cocaine seizures and quantity seized: trends and 2014 or most recent year
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Seizures Stopped shipments (1) TOTALS
Precursor/pre-precursor Cases Quantity Cases Quantity Cases Quantity
MDMA or related substances
PMK (litres) 1 5 0 0 1 5
Safrole (litres) 0 0 2 1 050 2 1 050
Piperonal (kg) 3 5 4 2 835 7 2 840
Glycidic derivatives of PMK (kg) 6 5 575 1 1 250 7 6 825
Amphetamine and methamphetamine
BMK (litres) 14 2 353 0 0 14 2 353
PAA, phenylacetic acid (kg) 1 100 2 190 3 290
Ephedrine, bulk (kg) 19 31 1 500 20 531
Pseudoephedrine, bulk (kg) 8 12 0 0 8 12
APAAN (kg) 18 6 062 1 5 000 19 11 062
(1) A stopped shipment is one that has been denied, suspended or voluntarily withdrawn by the exporter because of suspicion of diversion for illicit purposes.
TABLE 1.1
Summary of seizures and stopped shipments of precursors used for selected synthetic drugs produced in Europe, 2014
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I Amphetamine and methamphetamine 
Amphetamine and methamphetamine are closely related 
synthetic stimulants, generically known as amphetamines, 
and these are difficult to differentiate in some datasets. Of 
the two, amphetamine has always been the more common 
in Europe, but recent years have seen increasing reports of 
the availability of methamphetamine on the market. 
Both drugs are manufactured in Europe for domestic use. 
Some amphetamine and methamphetamine is also 
manufactured for export, principally to the Middle East, 
where there is a market for ‘captagon’ tablets — which are 
reported to contain amphetamines — the Far East and 
Oceania. Europe is also a transit hub for 
methamphetamine being trafficked from West Africa and 
Iran to markets in the Middle East. Amphetamine 
production mainly takes place in Belgium, the Netherlands, 
Poland, Germany, and to a lesser extent the Baltic States. 
A recent development has seen the relocation of the final 
production stage, with several countries now reporting the 
conversion of amphetamine base oil to amphetamine 
sulphate on their territories.
Much of Europe’s methamphetamine is produced in and 
around the Czech Republic. Some production capacity, 
however, also exists in the Netherlands and Lithuania, 
while Bulgaria has noted an increase in the number of 
laboratories dismantled.
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FIGURE 1.7
Number of amphetamine seizures and quantity seized: trends and 2014 or most recent year
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FIGURE 1.8
Number of methamphetamine seizures and quantity seized: trends and 2014 or most recent year
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Assessing recent trends in MDMA seizures is difficult due 
to the absence of data from some countries that are likely 
to make important contributions to this total. For 2014, no 
data are available from the Netherlands and the numbers 
of seizures are not available from Finland, France, Poland 
and Slovenia. The Netherlands reported seizing 2.4 million 
MDMA tablets in 2012, and if a similar figure may be 
assumed for 2014, it is estimated that around 6.1 million 
MDMA tablets were seized in the European Union in that 
year. This would be more than double the amount seized in 
2009. In addition, 0.2 tonnes of MDMA powder was seized 
in 2014. Large quantities of MDMA are also seized in 
Turkey, amounting to 3.6 million MDMA tablets in 2014 
(Figure 1.9). 
Among those countries reporting consistently, indexed 
trends also point to increases in MDMA-content since 
2010, and the availability of high MDMA-content 
products prompted joint alerts from Europol and the 
EMCDDA in 2014. 
Methamphetamine produced using BMK (benzyl methyl 
ketone) is reported by Lithuania and Bulgaria, while in and 
around the Czech Republic, ephedrine and 
pseudoephedrine is used. Historically, in the Czech 
Republic, methamphetamine has mainly been produced in 
small-scale facilities by users for their own or local use. 
This is reflected in the high number of production sites 
detected in this country (261 dismantled in 2013, out of 
294 in Europe). Recently, however, production volumes 
have been increasing and new pre-precursors have been 
used, with reports of organised crime groups producing 
this drug for both domestic and external markets. 
In 2014, 36 000 seizures of amphetamine were reported 
by EU Member States, amounting to 7.1 tonnes. Overall, 
the quantity of amphetamine seized in the European Union 
has increased since 2002 (Figure 1.7). Methamphetamine 
seizures are far lower, accounting for around a fifth of all 
amphetamines seizures in 2014, with 7 600 seizures 
reported in the European Union, amounting to 0.5 tonnes 
(Figure 1.8). Both number and quantity of 
methamphetamine seized show an upward trend 
since 2002. 
Typically, the average reported purity is higher for 
methamphetamine than for amphetamine samples. 
Although indexed trends suggest that amphetamine purity 
has increased in the latest data, the average purity of this 
drug continues to be relatively low.
I MDMA: increase in high-dose products
The synthetic substance MDMA (3,4-methylenedioxy-
methamphetamine) is chemically related to 
amphetamines, but differs in its effects. Ecstasy tablets 
have historically been the main MDMA product on the 
market, although they have often contained a range of 
MDMA-like substances and unrelated chemicals. After a 
period when reports suggested that the majority of tablets 
sold as ecstasy in Europe contained low doses of MDMA or 
none at all, recent evidence indicates that this situation 
has changed. Reports indicate an increased availability 
both of high-dose MDMA tablets and of MDMA in powder 
and crystal forms. 
Production of MDMA in Europe appears to be concentrated 
around the Netherlands, which has historically reported 
the largest numbers of production sites for this drug. After 
evidence of a decline in MDMA production at the end of 
the last decade, there have been signs of resurgence, 
illustrated by reports of large-scale production facilities 
recently dismantled in the Netherlands and in Belgium.
 High MDMA-content products  
 prompted joint alerts from  
 Europol and the EMCDDA 
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FIGURE 1.9
Number of MDMA seizures and quantity seized: trends and 2014 or most recent year
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of other substances. In 2015, 98 new substances were 
detected for the first time, bringing the number of new 
substances monitored to more than 560, of which 380 
(70 %) were detected in the last 5 years (Figure 1.10).
Since 2008, over 160 synthetic cannabinoids have been 
detected in a range of different products — including 24 
new cannabinoids reported in 2015. Synthetic 
cannabinoids are sold as ‘legal’ replacements for cannabis 
and may be advertised as ‘exotic incense blends’, and ‘not 
for human consumption’, in order to circumvent consumer 
protection and medicine laws. This is the largest group of 
new drugs monitored by the EMCDDA, reflecting both the 
large demand for cannabis within Europe and the ability of 
manufacturers to place new cannabinoids on the market 
when existing ones are subjected to control measures. 
Synthetic cathinones are the second largest group of 
substances monitored by the EMCDDA. These were first 
detected in Europe in 2004 and since then, 103 new 
cathinones have been identified, 26 in 2015. Synthetic 
cathinones are typically sold as ‘legal’ replacements for 
stimulants such as amphetamine, MDMA and cocaine.
The EMCDDA currently monitors 14 new and non-
controlled benzodiazepines. These are sometimes used by 
I Seizures of LSD, GHB, ketamine and mephedrone
A number of other illicit drugs are seized in the European 
Union, and among these were 1 700 seizures of LSD in 2014 
representing 156 000 doses. In addition, Belgium seized 
3 kg of the drug, the largest quantity ever recorded for that 
country. For most other drugs, incomplete datasets do not 
allow comparison between countries or analysis of trends. In 
2014, seizures of GHB or GBL were reported by 18 
countries. The 1 243 seizures amounted to 176 kg and 
544 litres of the drug, with Belgium (40 %) and Norway 
(34 %) each accounting for over a third of these seizures. 
Eleven countries reported 793 seizures of ketamine, 
amounting to 246 kg of the drug. Over half of these seizures 
were in the United Kingdom. The 1 645 seizures of 
mephedrone reported by 10 countries amounted to 203 kg 
of the drug. Almost all of the mephedrone seized was 
reported by the United Kingdom (101 kg) and Cyprus (99 kg).
I New psychoactive substances: market diversity
The EMCDDA monitors a broad range of new psychoactive 
substances. These include synthetic cannabinoids, 
synthetic cathinones, phenethylamines, opioids, 
tryptamines, benzodiazepines, arylalkylamines and a range 
FIGURE 1.10
Number and categories of new psychoactive substances notified to the EU Early Warning System for the first time, 2009–15
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counterfeiters to produce fake medicines that are sold in 
Europe. Examples of this practice include fake alprazolam 
tablets, intercepted in 2015, that were found to contain 
flubromazolam, and fake diazepam tablets which 
FIGURE 1.11
Number of seizures of new psychoactive substances reported to the EU Early Warning System: trends and by category in 2014
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FIGURE 1.12
Seizures of synthetic cannabinoids and cathinones reported to the EU Early Warning System: trends in number of seizures and quantity seized
contained phenazepam. In some European countries, 
these counterfeit medicines have become an important 
part of the illicit drug market.
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I  Increased seizures of new psychoactive substances
Case level seizure data reported to the EU Early Warning 
System point to the continued growth of the new drugs 
market. In 2014, almost 50 000 seizures of new 
substances, weighing almost 4 tonnes, were made across 
Europe (Figure 1.11). Synthetic cannabinoids accounted 
for the majority of these, with almost 30 000 seizures 
weighing more than 1.3 tonnes (Figure 1.12). Synthetic 
cathinones were the second largest group, with more than 
8 000 seizures weighing more than 1 tonne. Together, 
synthetic cannabinoids and cathinones accounted for 
almost 80 % of the total number of seizures and over 60 % 
of the quantity seized during 2014. Other groups included 
non-controlled benzodiazepines and potent narcotic 
analgesics, such as fentanyls, which may be sold as heroin.
Seizures of new psychoactive substances in 2014 were 
dominated by synthetic cannabinoids, which accounted for 
more than 60 % of the total number of seizures and almost 
35 % of the quantity seized (Figure 1.11). Most were 
powder seizures, often in bulk amounts; the rest was 
typically seized as plant material with the substance 
sprayed onto it. The powders are used to manufacture 
products sold as ‘legal highs’, and seizures represent 
millions of doses. The top five cannabinoids seized in 
powder form in 2014 were AM-2201 (70 kg), MDMB-
CHMICA (40 kg), AB-FUBINACA (35 kg), MAM-2201 
(27 kg) and XLR-11 (5F-UR-144) (26 kg).
In 2014, synthetic cathinones accounted for more than 
15 % of all seizures of new psychoactive substances and 
almost 30 % of the total quantity seized (Figure 1.11). The 
top five cathinones seized included mephedrone (222 kg) 
and its isomers 3-MMC (388 kg) and 2-MMC (55 kg) as 
well as pentedrone (136 kg) and alpha-PVP (135 kg). 
I Drug markets: policy responses
The global nature of illicit drug supply and trafficking 
means implementing counter measures is complex. A 
range of supply reduction options are available to 
policymakers including drug strategy and legal 
interventions alongside regulatory and law enforcement 
approaches. The coordination of European supply 
reduction initiatives is undertaken by a number of EU 
institutions. Several strategic planning tools are used in 
this process: the EU drugs strategy 2013–20 and its 
current action plan 2013–16, the EU policy cycle on 
organised and serious international crime and the EU 
security strategies. The breadth of the challenges facing 
law enforcement and the increasing sophistication of 
organised crime groups involved in the drugs trade is 
evident from the array of policy areas these strategies 
cover. These include, for example, the areas of security, 
maritime, migration and development policies. They span 
actions to enhance intelligence led policing, maritime 
surveillance and transportation, detection and targeting of 
illicit financial flows, border control, the movement of 
industrial chemicals, and alternative development 
measures. The European Union also cooperates with a 
range of international partners to implement these supply 
reduction policies. 
At the national level, Member States are required to 
address an equally complex set of drug market dynamics 
and most have national security and policing strategies 
that cover drug supply reduction. In addition, all but two 
countries use national drug strategies to express their drug 
policies often encompassing supply reduction alongside 
demand reduction initiatives. The exceptions are Austria, 
which has regional drug strategies, and Denmark, which 
has a national drug policy that is expressed in a range of 
strategic documents, legislation and concrete actions. 
Drug strategies are documents, usually time-limited, 
typically containing objectives and priorities, alongside 
specific actions and the parties responsible for 
implementing them. The drug policy arena has become 
increasingly complex in recent years. This is reflected in 
the situation with nearly a third of EU Member States’ 
national strategies having their scope extended beyond 
illicit drugs to encompass licit drugs and in some cases 
addictive behaviours (see Figure 1.13). 
 Countries use national drug  
 strategies to express their  
 drug policies 
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I Legal responses to drug supply and possession
Member States take measures to prevent the supply of 
illicit drugs under three United Nations Conventions, which 
provide an international framework for control of 
production, trade and possession of over 240 psychoactive 
substances. Each country is obliged to treat drug 
trafficking as a criminal offence, but the penalties written 
in the law vary between states. In some countries, drug 
supply offences may be subject to a single wide penalty 
range, while other countries differentiate between minor 
and major supply offences with corresponding penalty 
ranges. 
Each country is also obliged to treat possession of drugs 
for personal use as a criminal offence, but subject to a 
country’s ‘constitutional principles and the basic concepts 
of its legal system’. This clause has not been uniformly 
interpreted, and this is reflected in different legal 
approaches in European countries and elsewhere. Since 
around 2000, there has been an overall trend across 
Europe towards reducing the likelihood of imprisonment or 
other incarceration for minor offences related to personal 
drug use. Some countries have gone further, so that 
possession of drugs for personal use can only be punished 
by non-criminal sanctions, usually a fine (Figure 1.14).
I Drug law offences: longer term increases
The implementation of laws to curb drug supply and use is 
monitored through data on reported drug law offences. In 
the European Union, there were an estimated 1.6 million 
offences reported (most of them related to cannabis; 57 %) 
in 2014, involving around 1 million offenders. Reported 
offences increased by almost a third (34 %) between 2006 
and 2014.
In most European countries, the majority of reported drug 
law offences relate to use or possession for use. In Europe, 
overall, it is estimated that more than 1 million of these 
offences were reported in 2014, a 24 % increase compared 
with 2006. Of the reported drug offences related to 
possession, more than three-quarters involve cannabis. 
The upward trends in offences for cannabis, 
amphetamines and MDMA possession have continued in 
2014 (Figure 1.15).
FIGURE 1.13 FIGURE 1.14
National drug strategies and action plans: availability and scope Penalties in laws: possibility of incarceration for possession of 
drugs for personal use (minor offences)
Combined licit and illicit
Illicit only
Regional or other strategies
For any minor drug possession
Incarceration possible
Not for minor cannabis 
possession, but possible 
for other drug possession
Not for minor 
drug possession
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Overall, reports of drug supply offences have increased by 
10 % since 2006, reaching an estimate of more than 
214 000 cases in 2014. As with possession offences, 
cannabis accounted for the majority. Cocaine, heroin and 
amphetamines, however, accounted for a larger share of 
offences for supply than for personal possession. The 
downward trends in offences for heroin and cocaine supply 
have not continued into 2014, and there has been a sharp 
increase in reports of supply offences for MDMA 
(Figure 1.15).
I Preventing the diversion of substitution medicines
The diversion of opioid substitution medicines from their 
intended use in drug treatment to non-medical use and 
sale on illicit drug markets is a cause for concern. 
Diversion here refers to the sharing, selling, trading, or 
giving away of prescription medications to others. This may 
occur voluntarily (intentional supply to another person) 
or involuntarily (inadvertent supply such as lost doses 
and theft). 
At a national level, various strategies are implemented to 
prevent diversion of substitution medicines. These include 
providing training for clinicians and patients; implementing 
strategies to assure treatment compliance by appropriate 
prescription and supervision of dosing; providing medicine 
formulations designed to deter misuse; use of electronic 
medicine dispensers; and employing control measures 
such as patient toxicology tests, pill counts, and 
unannounced monitoring. Regulation at a system level 
may occur through registers of pharmacy transactions and 
use of disciplinary measures to address inappropriate 
prescribing.
A recent European review suggests that many of these 
interventions have the potential to reduce the occurrence 
of diversion, although information on the possible 
unintended consequences of their implementation is rarely 
reported. At present, the challenge remains one of 
maintaining good patient access to substitution medicines 
while establishing appropriate prevention and regulation 
responses that minimise the leakage of these medicines 
onto the illicit market. 
FIGURE 1.15
Drug law offences in Europe related to drug use or possession for use or drug supply: indexed trends and reported offences in 2014
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Drug use in Europe now encompasses 
a wider range of substances than in the 
past. Among drug users, polydrug 
consumption is common and individual 
patterns of use range from experimental 
to habitual and dependent 
consumption. Use of all drugs is 
generally higher among males, and this 
difference is often accentuated for more 
intensive or regular patterns of use. The 
prevalence of cannabis use is about five 
times that of other substances. While 
the use of heroin and other opioids 
remains relatively rare, these continue 
to be the drugs most commonly 
associated with the more harmful forms 
of use including injecting drug use. 
I One in four Europeans have tried illicit drugs
Over 88 million adults, or just over a quarter of the 15- to 
64-year-olds in the European Union, are estimated to have 
tried illicit drugs at some point in their lives. Drug use is 
more frequently reported by males (54.3 million) than 
females (34.8 million). The most commonly used drug is 
cannabis (51.5 million males and 32.4 million females), 
with much lower estimates reported for the lifetime use of 
cocaine (11.9 million males and 5.3 million females), 
MDMA (9.1 million males and 3.9 million females) and 
amphetamines (8.3 million males and 3.8 million females). 
Levels of lifetime use of cannabis differ considerably 
between countries, ranging from around four in 10 adults 
Drug use prevalence and 
trends
Monitoring drug use
The EMCDDA collects and maintains datasets that 
cover drug use and patterns of use in Europe. 
Data from general population surveys can provide an 
overview of the prevalence of recreational drug use. 
These survey results can be complemented by 
community level analyses of drug residues in 
municipal wastewater, carried out in cities across 
Europe. 
Studies reporting estimates of high-risk drug use can 
help to identify the extent of the more entrenched 
drug use problems, while data on those entering 
specialised drug treatment systems, when 
considered alongside other indicators, can inform 
understanding on the nature and trends in high-risk 
drug use. 
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in France and one-third of adults in Denmark and Italy, to 
less than one in 10 in Bulgaria, Hungary, Malta, Romania 
and Turkey.
Last year drug use provides a good measure of recent drug 
use and is largely concentrated among young people 
(15–34). An estimated 17.8 million young adults used 
drugs in the last year, with males outnumbering females by 
a factor of two. 
I Cannabis use: different national pictures
Across all age groups, cannabis is the illicit drug most likely 
to be used. The drug is generally smoked and, in Europe, is 
commonly mixed with tobacco. Patterns of cannabis use 
can range from the occasional to the regular and 
dependent. 
An estimated 16.6 million young Europeans (aged 15–34), 
or 13.3 % of this age group, used cannabis in the last year, 
with 9.6 million of these aged 15–24 (16.4 % of this 
age group). Among young people using cannabis in the 
last year, the ratio of males to females is two to one. 
The most recent survey results show that countries 
continue to follow divergent paths in last year cannabis 
use (Figure 2.1). Of the countries that have produced 
surveys since 2013, eight reported higher estimates, four 
were stable and one reported a lower estimate than in the 
previous comparable survey. 
Only a limited number of countries have sufficient survey 
data to allow a statistical analysis of medium and long-
term trends in last year cannabis use among young adults 
(15–34). Surveys for relatively high-prevalence countries, 
such as Germany, Spain and the United Kingdom, all show 
decreasing or stable cannabis prevalence over the past 
decade, while France shows increases in prevalence after 
2010. Among countries that have historically lower rates of 
cannabis use, Finland has consistently reported increases 
in prevalence over the long term, moving from a low 
prevalence towards the European average, while Sweden 
retains a low level with data showing a modest increase 
over the last decade. Among the countries with fewer 
comparable data points, the Bulgarian data continues an 
increasing trend until 2012, while an annual survey in the 
Czech Republic found increases from 2011 to 2014.
FIGURE 2.1
Last year prevalence of cannabis use among young adults (15–34): 
most recent data (top) and statistically significant trends (centre 
and bottom)
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Cannabis accounted for the majority of illicit drug use 
among 15- to 16-year-old school students reported by the 
last round of the European School Survey Project on 
Alcohol and Other Drugs (ESPAD), published in 2011. 
More recent data on schoolchildren, in this case aged 15, 
are provided by the Health Behaviour in School-aged 
Children (HBSC) study. In the 2013/14 HBSC survey, 
levels of lifetime cannabis use ranged from 5 % among 
girls and 7 % among boys in Sweden to 26 % among girls 
and 30 % among boys in France.
I Treating cannabis users: increased demand
Based on surveys of the general population, it is estimated 
that around 1 % of European adults are daily or almost 
daily cannabis users — that is, they have used the drug on 
20 days or more in the last month. Around 60 % of these 
are aged between 15 and 34 years, and over three-
quarters are male. 
When considered alongside other indicators, data on those 
entering treatment for cannabis problems can inform 
understanding of the nature and scale of high-risk 
cannabis use in Europe. Overall, the number of first-time 
treatment entrants for cannabis problems increased from 
45 000 in 2006 to 69 000 in 2014. Among this group, 
those reporting daily use of the substance rose from 46 % 
in 2006 to 54 % in 2014. The causes of the increase in the 
number of treatment entrants are unclear, but may be 
linked to changes in the prevalence of cannabis use and 
intensive use and other factors such as the availability of 
more harmful and higher-potency products, an increase in 
cannabis treatment availability and changing treatment 
referral practices.
CANNABIS USERS ENTERING TREATMENT
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I Cocaine: changing prevalence
Cocaine is the most commonly used illicit stimulant drug 
in Europe, although its use is more prevalent in the south 
and west of Europe. Cocaine powder (cocaine 
hydrochloride) is primarily sniffed (nasal insufflation), but 
is also sometimes injected, whereas crack cocaine 
(cocaine base) is usually smoked. 
It is estimated that about 2.4 million young adults aged 15 
to 34 (1.9 % of this age group) used cocaine in the last 
year. Many cocaine users consume the drug recreationally, 
with use highest during weekends and holidays. Among 
regular users, a broad distinction can be made between 
more socially integrated consumers, who often sniff 
powder cocaine, and marginalised users, who inject 
cocaine or smoke crack sometimes alongside the use of 
opioids.
Only Spain, the Netherlands and the United Kingdom 
report last year prevalence of cocaine use among young 
adults of 3 % or more. The decreases in cocaine use 
FIGURE 2.2
Last year prevalence of cocaine use among young adults (15–34): statistically significant trends and most recent data
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reported in previous years have not been observed in the 
most recent surveys; of the countries that have produced 
surveys since 2013, six reported higher estimates, two 
reported a stable trend and four reported lower estimates 
than in the previous comparable survey. 
A statistical analysis of long-term trends in last year use of 
cocaine among young adults is only possible for a small 
number of countries. Spain and the United Kingdom both 
reported trends of increasing prevalence until 2008, 
followed by stability or decline. Reports from the United 
Kingdom suggest that this decline is limited to younger 
adults (16–24), with prevalence in the older age group 
remaining stable or increasing. France has an increasing 
trend, moving above 2 % in 2014. In Finland, prevalence 
has increased but the overall levels of use remain low, only 
reaching 1 % for the first time in 2014. 
Analysis of municipal wastewater for cocaine residues 
carried out in a multi-city study complements the results 
from population surveys. The results of the study are 
presented in standardised amounts (mass loads) of drug 
residue per 1 000 population per day. The 2015 analysis 
found the highest mass loads of benzoylecgonine — the 
main metabolite of cocaine — in cities in Belgium, Spain, 
the Netherlands and the United Kingdom (see Figure 2.3). 
The general patterns detected in 2015 are similar to those 
in previous years, with most cities showing either a 
decreasing or a stable trend between 2011 and 2015.
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I Treating cocaine use: stable demand
The prevalence of particularly problematic patterns of 
cocaine use in Europe is difficult to gauge as only five 
countries have recent estimates and different definitions 
and methodologies have been used. In 2012, Germany 
estimated cocaine-dependency among the adult 
population at 0.20 %. In 2014, Italy produced an estimate 
of 0.64 % for those in need of treatment for cocaine use 
and in 2013, Spain estimated high-risk cocaine use at 
FIGURE 2.3
Cocaine residues in wastewater in selected European cities: trends and most recent data
NB: Mean daily amounts of benzoylecognine in milligrams per 1 000 population. Map: from sampling over a one-week period in 2015. 
Source: Sewage Analysis Core Group Europe (SCORE).
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0.29 %. For 2011/2012, the United Kingdom estimated 
crack cocaine use among the adult population in England 
at 0.48 % and the majority of these were also opioid users. 
High-risk cocaine use in Portugal is estimated at 0.62 %, 
based on reported last year use. 
Spain, Italy and the United Kingdom account for 74 % of all 
reported treatment entries related to cocaine in Europe. 
Overall, cocaine was cited as the primary drug by 60 000 
clients entering specialised drug treatment in 2014 and by 
27 000 first-time clients. After a period of decline, the 
overall number of cocaine first-time treatment entrants has 
been stable since 2012. 
In 2014, almost 5 500 clients entering treatment in Europe 
reported primary crack cocaine use, with the United 
Kingdom accounting for more than half of these (3 000), 
and Spain, France and the Netherlands most of the 
remainder (2 000).
I MDMA: changing trends and increasing use
MDMA (3,4-methylenedioxy-methamphetamine) is 
commonly used in the form of ecstasy tablets, but is also 
increasingly available as crystals and powders; tablets are 
usually swallowed, but in powder form the drug is also 
snorted (nasal insufflation). 
In recent years, monitoring sources based in a number of 
countries have been signalling new developments within 
Europe’s MDMA market, including reports of increased 
use.
Most European surveys have historically collected data on 
ecstasy rather than MDMA use, although this is now 
changing. It is estimated that 2.1 million young adults 
(15–34) used MDMA/ecstasy in the last year (1.7 % of this 
age group), with national estimates ranging from 0.3 % to 
5.5 %. Among young people using MDMA in the last year, 
the ratio of males to females is 2.4 to 1.
Until recently, in many countries, MDMA prevalence has 
been on the decline from peak levels attained in the early 
to mid-2000s. This appears now to be changing. Among 
the countries that have produced new surveys since 2013, 
results point to an overall increase in Europe, with nine 
countries reporting higher estimates and three reporting 
lower estimates than in the previous comparable survey. 
Where data exist for a more robust analysis of trends in 
FIGURE 2.4
Last year prevalence of MDMA use among young adults (15–34): statistically significant trends and most recent data
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last year use of MDMA among young adults, increases are 
observed in some countries since 2010. Bulgaria, Finland 
and France all continue long-term upward trends over this 
period, while in the United Kingdom a break in 2011/2012 
from a downward trend is followed by statistically 
significant increases (Figure 2.4). Though not directly 
comparable with earlier surveys, the Netherlands reports a 
prevalence of 5.5 % in 2014.
A 2015 multi-city analysis found the highest mass loads of 
MDMA in the wastewater of Belgian and Dutch cities 
(Figure 2.5). In most cities, wastewater MDMA loads were 
higher in 2015 than in 2011, with sharp increases 
observed in some cities, which may be related to the 
increased purity of MDMA or increased availability and 
consumption of the drug. 
MDMA is often taken alongside other substances, including 
alcohol. Typically, surveys of young people who regularly 
attend nightlife events indicate higher levels of drug use 
compared with the general population. This is particularly the 
case for MDMA, which has historically been closely linked 
with nightlife settings and especially with electronic dance 
music. Current indications suggest that in higher-prevalence 
countries, the use of MDMA is no longer a niche or 
subcultural drug; it is not limited to dance clubs and parties, 
but is used by a wider range of young people in mainstream 
nightlife settings such as bars and house parties.
MDMA use is rarely cited as a reason for entering 
specialised drug treatment. In 2014, MDMA was reported 
by less than 1 % (almost 800 cases) of first-time treatment 
entrants in Europe.
FIGURE 2.5
MDMA residues in wastewater in selected European cities: trends and most recent data
NB: Mean daily amounts of MDMA in milligrams per 1 000 population. Map: from sampling over a one-week period in 2015. 
Source: Sewage Analysis Core Group Europe (SCORE).
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I Amphetamines use: divergent national trends 
Amphetamine and methamphetamine, two closely related 
stimulants, are both consumed in Europe, although 
amphetamine is by far the more commonly used. 
Methamphetamine consumption has historically been 
restricted to the Czech Republic and, more recently, 
Slovakia, although recent years have seen increases in use 
in other countries. In some data sets, it is not possible to 
distinguish between these two substances; in these cases, 
the generic term amphetamines is used. 
Both drugs can be taken orally or nasally; in addition, 
injection is common among high-risk users in some 
countries. Methamphetamine can also be smoked, but this 
route of administration is not commonly reported in Europe.
An estimated 1.3 million (1.0 %) young adults (15–34) 
used amphetamines during the last year, with the most 
recent national prevalence estimates ranging from 0.1 % to 
2.9 %. The available data suggest that since around 2000, 
most European countries have experienced a relatively 
stable situation in respect to trends in use. Of the countries 
that have produced surveys since 2013, seven reported 
higher estimates, one reported a stable trend and four 
reported lower estimates than in the previous comparable 
survey. Although not comparable with earlier surveys, the 
Netherlands recently reported a prevalence of 2.9 % 
among young adults. 
In the limited number of countries where it is possible to 
analyse longer term statistically significant trends, both 
Spain and the United Kingdom show a decrease in 
prevalence since 2000 (Figure 2.6). In contrast, Finland 
has shown a steady increase in prevalence over the same 
period and now reports one of the highest levels in Europe. 
Analysis of municipal wastewater carried out in 2015 
found amphetamines at appreciable levels in cities across 
Europe. The mass loads of amphetamine varied 
considerably, with the highest levels reported in cities in 
the north of Europe (see Figure 2.7). Amphetamine was 
found at much lower levels in cities in the south of Europe. 
The highest mass loads of methamphetamine were found 
in cities in the Czech Republic, Slovakia and Norway. 
Overall, the data from 2011 to 2015 showed relatively 
stable trends for both drugs.
FIGURE 2.6
Last year prevalence of amphetamines use among young adults (15–34): statistically significant trends and most recent data
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FIGURE 2.7
Amphetamine residues in wastewater in selected European cities: trends and most recent data
mg/1 000 population/day
NB: Mean daily amounts of amphetamine in milligrams per 1 000 population. Map: from sampling over a one-week period in 2015. 
Source: Sewage Analysis Core Group Europe (SCORE).
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I Treating amphetamine users: rising demand 
Problems related to long-term, chronic and injecting 
amphetamine use have, historically, been most evident in 
northern European countries. In contrast, long-term 
methamphetamine problems have been most apparent in 
the Czech Republic and Slovakia. Recent estimates of 
high-risk use of methamphetamine are available for the 
Czech Republic and Cyprus. In the Czech Republic, 
high-risk methamphetamine use among adults (15–64) 
was estimated at around 0.51 % for 2014, with a marked 
increase in use, mainly injecting, observed between 2007 
and 2014 (from around 20 000 users to over 36 000). The 
estimate for Cyprus is 0.02 % or 127 users in 2014. For 
Norway, in 2013, high-risk use of amphetamine and 
methamphetamine is estimated at 0.33 % or 11 200 
adults. Users of amphetamines are likely to make up the 
majority of the estimated 2 177 (0.17 %) high-risk 
stimulant users reported by Latvia, down from 6 540 
(0.46 %) in 2010. 
Injection of methamphetamine alongside use of other 
stimulants and GHB (gamma-hydroxybutyrate) continues 
to be reported in a number of countries among small 
groups of men who have sex with men. These so-called 
slamming practices are a concern because of the 
combination of risk-taking in both drug use and sexual 
behaviours.
Approximately 32 000 clients entering specialised drug 
treatment in Europe in 2014 reported amphetamines as 
their primary drug, of whom around 13 000 were first-time 
clients. Primary amphetamine users account for a sizeable 
proportion of reported first-time treatment entrants in 
Bulgaria, Germany, Latvia, Hungary, Poland and Finland. 
Treatment entrants reporting primary methamphetamine 
use are concentrated in the Czech Republic and Slovakia, 
which together account for almost 95 % of the 8 700 
methamphetamine clients in Europe. Overall, Europe has 
seen a 50 % increase in the number of first-time entrants 
for primary use of amphetamines since 2006, largely 
driven by increases in Germany and, to a lesser extent, the 
Czech Republic.
I Use of ketamine, GHB and hallucinogens
A number of other substances with hallucinogenic, 
anaesthetic, dissociative and depressant properties are 
used in Europe: these include LSD (lysergic acid 
diethylamide), hallucinogenic mushrooms, ketamine and 
GHB (gamma-hydroxybutyrate). 
The recreational use of ketamine and GHB (including its 
precursor GBL, gamma-butyrolactone) has been reported 
among subgroups of drug users in Europe for the last two 
decades. Where they exist, national estimates of the 
prevalence of GHB and ketamine use in both adult and 
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school populations remain low. In their most recent 
surveys, the Netherlands reported last year prevalence of 
GHB use at 0.4 % for adults (15–64) and Norway at 0.1 % 
(16–64), while and Romania reported 0.5 % for young 
adults (15–34). Higher levels of both GHB use and related 
problems have been reported among particular social 
groups at the city and local level in some countries, 
including the Netherlands, Norway and the United 
Kingdom. Last year prevalence of ketamine use among 
young adults (15–34) was estimated at 0.3 % in Denmark 
and Spain, and the United Kingdom reported last year 
ketamine use at 1.6 % among 16- to 24-year-olds, a stable 
trend since 2008. 
The overall prevalence levels of LSD and hallucinogenic 
mushroom use in Europe have been generally low and 
stable for a number of years. Among young adults (15–34), 
national surveys report last year prevalence estimates of 
less than 1 % for both substances, with the exception of 
Finland with a prevalence of 1.3 % for LSD, and for 
hallucinogenic mushrooms the United Kingdom (1 %), 
the Netherlands (1.3 %), Finland (1.9 %) and the 
Czech Republic (2.3 %).
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I Use of new drugs
Insights into the use of new drugs are provided by the 
2014 Flash Eurobarometer on young people and drugs, a 
telephone survey of 13 128 young adults aged 15–24 in 
the 28 EU Member States. Although primarily an attitudinal 
survey, the Eurobarometer includes a question on the use 
of ‘substances that imitate the effects of illicit drugs’. 
Currently, these data represent the only EU-wide 
information source on this topic, although for 
methodological reasons caution is required when 
interpreting the results. Overall, 8 % of respondents 
reported lifetime use of such substances, with 3 % 
reporting use in the last year. This represents an increase 
from the 5 % reporting lifetime use in a similar survey in 
2011. Of those reporting use in the last year, 68 % had 
obtained the substance from a friend.
An increasing number of countries are including new 
psychoactive substances in their general population 
surveys, though differences in methods and questions limit 
the comparability of the results between countries. Since 
2011, 11 European countries have reported national 
estimates of the use of new psychoactive substances (not 
including ketamine and GHB). For the age group covered 
in the Flash Eurobarometer study, younger adults (aged 
15–24), last year prevalence of use of these substances 
ranges from 0.0 % in Poland to 9.7 % in Ireland. Survey 
data for the United Kingdom (England and Wales) are 
available on the use of mephedrone. In the most recent 
survey (2014/15), last year use of this drug among young 
people aged 16 to 24 was estimated at 1.9 %; this figure 
was the same as the previous survey, but down from 4.4 % 
in 2010/11, before control measures were introduced. In 
2014, a survey in Finland estimated last year use of 
synthetic cathinones to be 0.2 % among young people 
aged 15 to 24, while in France an estimated 4 % of 18- to 
34-year-olds reported having ever smoked synthetic 
cannabinoids.
I Heroin users: stable treatment demand
In Europe, the most commonly used illicit opioid is heroin, 
which may be smoked, snorted or injected. A range of 
synthetic opioids such as methadone, buprenorphine and 
fentanyl are also misused.
The average prevalence of high-risk opioid use among 
adults (15–64) is estimated at 0.4 %, the equivalent of 1.3 
million high-risk opioid users in Europe in 2014. At national 
level, prevalence estimates of high-risk opioid use range 
from less than 1 to around 8 cases per 1 000 population 
aged 15–64 (Figure 2.8). Around 75 % of the estimated 
high-risk opioid users in the European Union are reported 
in the United Kingdom, France, Italy, Germany and Spain. 
Of the 11 countries with repeated estimates of high-risk 
opioid use between 2008 and 2014, Spain and Turkey 
show a statistically significant decrease, with stable trends 
in the other countries (Figure 2.8).
Europe has experienced different waves of heroin 
addiction, the first affecting many western countries from 
the mid-1970s and a second wave affecting other 
countries especially those in central and eastern Europe in 
the mid to late 1990s. Subsequently there has been 
diffusion from urban centres to more rural areas and 
smaller cities in some countries. From 2010/11, indicators 
in many European countries highlighted a decline in new 
recruitment into heroin use and the existence of an ageing 
cohort of high-risk opioid users, many of whom were 
receiving substitution treatment. The most recent data 
suggest the downward trend in new treatment entrants 
may be levelling off.
 In Europe, the most  
 commonly used illicit  
 opioid is heroin 
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FIGURE 2.8
National estimates of last year prevalence of high-risk opioid use: selected trends and most recent data
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Of the 185 000 clients reporting opioids as their primary 
drug who entered specialised treatment in Europe, 34 000 
were first-time entrants. The number of new heroin clients 
has more than halved from a peak of 59 000 in 2007, when 
they accounted for 36 % of all new clients, to 23 000 in 
2013 (16 % of new clients). The trend seems to have 
levelled off. In the latest data, 17 countries reported a 
stable or declining number of new heroin clients, whereas 
9 reported an increase. 
I Synthetic opioids: an increasing concern 
While heroin remains the most commonly used opioid, 
synthetic opioids are being increasingly misused. In 2014, 
18 European countries reported that more than 10 % of all 
opioid clients entering specialised services presented for 
problems primarily related to opioids other than heroin 
(Figure 2.9); an increase from 11 countries in 2013. 
Opioids reported by treatment entrants include 
methadone, buprenorphine, fentanyl, codeine, morphine, 
tramadol and oxycodone. In some countries, non-heroin 
opioids now represent the most common form of opioid 
use among treatment entrants. In Estonia, for example, the 
majority of treatment entrants reporting an opioid as their 
primary drug were using fentanyl, while in Finland and the 
Czech Republic, buprenorphine is the most frequently 
misused non-heroin opioid. 
 Synthetic opioids are being  
 increasingly misused 
FIGURE 2.9
Treatment entrants citing opioids as primary drug: by type of opioid (left) and percentage reporting opioids other than heroin (right)
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I Injecting drug use: heroin in decline
Injecting drug use is most commonly associated with 
opioids, although in a few countries, the injection of 
stimulants such as amphetamines or cocaine is a major 
problem. The injection of synthetic cathinones, although 
not a widespread phenomenon, continues to be reported 
in some specific populations, including opioid injectors, 
drug treatment clients in some countries and small 
populations of men who have sex with men. Recent 
estimates of the prevalence of injecting drug use are 
available for 16 countries, where they range from less than 
1 to more than 9 cases per 1 000 population aged 15–64.
Among first-time clients entering drug treatment in 2014 
with heroin as their primary drug, 33 % reported injecting 
as their main route of administration, down from 43 % in 
2006 (Figure 2.10). In this group, levels of injecting vary 
between countries, from 11 % in Spain to more than 90 % 
in Latvia and Romania. Among first-time clients with 
amphetamines as their primary drug, 47 % report injecting 
as their main route of administration, with a small overall 
increase since 2006. More than 70 % of this group are 
from the Czech Republic and users of methamphetamine. 
Taking the main three injected drugs together, among 
first-time entrants to treatment in Europe, injecting as the 
main route of administration has declined from 28 % in 
2006 to 20 % in 2014.
 Injecting drug use is most  
 commonly associated with  
 opioids 
FIGURE 2.10
First-time treatment entrants reporting injecting as the main route 
of administration of their primary drug
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Drug-related harms and 
responses
Chapter 3
Illicit drug use is a recognised 
contributor to the global burden of 
disease. Chronic and acute health 
problems are associated with the use of 
illicit drugs, and these are compounded 
by various factors including the route of 
administration, individual vulnerability 
and the social context in which drugs 
are consumed. Chronic problems 
include dependence and drug-related 
infectious disease, while there is a range 
of acute harms, some of which depend 
on the drug consumed, with drug 
overdose the best documented of these. 
Although relatively rare, the use of 
opioids still accounts for much of the 
morbidity and mortality associated with 
drug use. Risks are elevated through 
injecting drug use. In comparison, 
although the health problems 
associated with cannabis use are clearly 
lower, the high prevalence of use of this 
drug may have implications for public 
health. Commenting on the harms 
linked to the use of new psychoactive 
substances is difficult because of both 
the number of substances in this group 
and the lack of information on them.
Monitoring drug-related harms and responses
Drug-related infectious diseases and mortality and 
morbidity associated with drug use are the principal 
harms monitored systematically by the EMCDDA. 
These are complemented by more limited data on 
acute drug-related hospital presentations and data 
from the EU Early Warning System, which monitors 
harms associated with new psychoactive 
substances. Further information is available online 
under Key epidemiological indicators, the Statistical 
Bulletin and the Early Warning System.
Information on health and social responses to drug 
use and related harms are provided to the EMCDDA 
by Reitox national focal points and expert working 
groups. Expert ratings provide supplementary 
information on the availability of interventions where 
more formalised datasets are unavailable. This 
chapter is also informed by reviews of the scientific 
evidence on the effectiveness of public health 
interventions. Supporting information can be found 
on the EMCDDA website in the Health and social 
responses profiles and the Best practice portal.
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Drug prevention and early intervention approaches aim to 
prevent drug use and related problems, while drug 
treatment, including both psychosocial and 
pharmacological approaches, represents the primary 
response to dependence. Some core interventions, such 
as opioid substitution treatment and needle and syringe 
programmes, were developed in part as a response to 
injecting opioid use and related problems, particularly the 
spread of infectious diseases and overdose deaths. 
I Cannabis harms: new research insights
While research frequently highlights associations between 
drug use and various harms, causality is more difficult to 
demonstrate. As Europe’s most prevalent drug, harms 
associated with cannabis use may have an impact at a 
population level. A recent international (WHO) review 
analysed the evidence around cannabis-related harms. It 
concluded that, while a causal relationship between the 
consumption of cannabis and health and social 
consequences is difficult to establish, some associations 
can be derived from observational studies. In terms of 
adverse effects of chronic cannabis use, regular and 
long-term cannabis users were found to have twice the risk 
of experiencing psychotic symptoms and disorders, a 
higher risk of developing respiratory problems and could 
develop a dependence syndrome. Regular cannabis use in 
adolescence was linked with increased risk of being 
diagnosed with schizophrenia, and if use continued 
throughout young adulthood, it appeared to be associated 
with intellectual impairment. Nevertheless, the role of 
pre-existing somatic and mental health conditions and 
other confounding factors may play a role, and this is a 
topic warranting further research.
I Prevention: family-based programmes
The use of cannabis by young people, often alongside the 
use of alcohol and tobacco, is one of the focuses for 
prevention strategies in Europe. The prevention of drug use 
and drug-related problems among young people 
encompasses a wide range of approaches. Environmental 
and universal strategies target entire populations, selective 
prevention targets vulnerable groups who may be at 
greater risk of developing drug use problems, and 
indicated prevention focuses on at-risk individuals.
Many drug prevention activities take place in school 
settings, where a relatively robust evidence base exists for 
some approaches. Similarly, interventions that target 
families have been positively evaluated in the prevention of 
a range of problem behaviours including drug use.
Family-based prevention programmes typically train 
parents to support their children to achieve age-specific 
developmental outcomes (including impulse control, social 
competence and gratification delay) that are associated 
with reduced risk of substance use and other behavioural 
problems. Family-based universal prevention is targeted at 
all families in the population, with interventions focusing 
on different stages of a child’s development, whereas 
selective programmes address marginalised and 
vulnerable families, including those affected by parental 
substance use problems. Although prevention 
interventions for vulnerable families exist in the majority of 
countries, expert ratings from 2013 indicate that their 
coverage is often limited. 
Relatively little is known about the contents of many 
family-based interventions. One exception is the 
Strengthening Families Programme, which provides 
training in parenting skills, and has now been implemented 
in 13 European countries. This internationally 
recommended programme also seeks to remove obstacles 
to participation for vulnerable parents, by providing 
transport and childcare. 
New approaches have also been developed that are 
time-limited and require fewer resources to implement. 
The EFFEKT programme for example, consisting of a few 
short sessions, has shown that improved parental 
monitoring and rule-setting can be effective in curbing 
alcohol use and improving impulse control among young 
people in the Netherlands and Sweden.
 Many drug prevention  
 activities take place in  
 school settings 
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treatment referrals came from this source. Overall trends in 
sources of referral have remained largely stable between 
2006 and 2014. 
In a number of countries, schemes are in place to divert 
drug offenders away from the criminal justice system and 
into drug treatment programmes. This may involve a court 
order to attend treatment or a suspended sentence 
conditional on treatment, but in some countries diversion 
is also possible at earlier stages. 
I Specialised treatment: referral paths
For the relatively small but significant number of 
individuals who experience problems with their drug use, 
including dependence, drug treatment is the primary 
intervention. Ensuring good access to appropriate 
treatment services is a key policy aim. 
Insight into the paths and routes individuals take into drug 
treatment is provided by data on sources of referral. In 
2014, 45 % of clients entering specialised drug treatment 
in Europe were either self-referred or referred by a family 
member, although this varied by drug (see Figure 3.1) and 
by country. Overall, a quarter of treatment entrants were 
referred by health services and 17 % by the criminal justice 
system. Of all treatment clients, cannabis clients were the 
most likely to be referred by the criminal justice system. In 
Hungary, around three-quarters (74 %) of cannabis 
FIGURE 3.1
Source of referral of clients entering specialised drug treatment in Europe in 2014
Referrals for each drug Trends 2006–14
Self-referred Health system Criminal justice
system
Other Educational
sevices
NB:  ‘Self-referral’ includes the client, family and friends; ‘health system’ includes general practitioners, other drug treatment centres and health, medical and 
social services; ‘criminal justice system’ includes courts, police and probation. In the trends graph, referrals via educational services are included under ‘other’.
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I Drug treatment: most often in outpatient settings
An estimated 1.2 million people received treatment for 
illicit drug use in the European Union during 2014 
(1.5 million including Norway and Turkey). Opioid users 
represent the largest group undergoing specialised 
treatment and consume the greatest share of available 
treatment resources, mainly in the form of substitution 
treatment. Cannabis and cocaine users are the second 
and third largest groups entering these services 
(Figure 3.2), with psychosocial interventions the main 
treatment modality for these clients. Differences between 
countries, however, can be very large, with opioid users 
accounting for up to 88 % of treatment entrants in some 
countries and less than 10 % in some others. 
Most drug treatment in Europe is provided in outpatient 
settings, with specialised outpatient centres representing 
the largest provider in terms of number of drug users 
treated (Figure 3.3). Healthcare centres are the second 
largest providers. This category includes general 
practitioners’ surgeries, which are important prescribers of 
opioid substitution treatment in some large countries such 
as Germany and France. Elsewhere, for example in 
Slovenia and Finland, mental healthcare centres may play 
a central role in outpatient treatment provision. 
A smaller proportion of drug treatment in Europe is 
provided in inpatient settings, including hospital-based 
residential centres (e.g. psychiatric hospitals), therapeutic 
communities and specialised residential treatment 
centres. The relative importance of outpatient and 
inpatient provision within national treatment systems 
varies greatly between countries. Expert opinion can 
provide an overview of the availability of selected 
interventions in different treatment settings in Europe (see 
Figure 3.4). 
Increasingly, a wide range of drug prevention and 
treatment interventions are provided online. Internet-based 
interventions have the potential to extend the reach and 
geographical coverage of treatment programmes to people 
experiencing drug use problems who may not otherwise 
access specialist drug services.
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FIGURE 3.4
Overview of high availability (>75 %) of selected interventions by setting (expert ratings)
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FIGURE 3.5
Percentage of high-risk opioid users receiving substitution treatment (estimate)
I Substitution treatment for opioid use problems
Substitution treatment, typically combined with 
psychosocial interventions, is the most common treatment 
for opioid dependence. The available evidence supports 
this approach, with positive outcomes found in respect to 
treatment retention, illicit opioid use, reported risk 
behaviour and drug-related harms and mortality. 
An estimated 644 000 opioid users received substitution 
treatment in the European Union in 2014 (680 000 
including Norway and Turkey), and numbers have fallen by 
around 50 000 since 2010. Estimates of opioid users 
would suggest that overall at least 50 % receive 
substitution treatment. However, this estimate must be 
treated with caution for methodological reasons and there 
are considerable national differences (Figure 3.5).
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Methadone is the most commonly prescribed opioid 
substitution drug, received by 61 % of substitution clients. 
A further 37 % of clients are treated with buprenorphine-
based medications, which is the principal substitution drug 
in seven countries (Figure 3.6). Other substances, such as 
slow-release morphine or diacetylmorphine (heroin), are 
more rarely prescribed, being received by an estimated 2 % 
of substitution clients in Europe. 
Although less common than substitution treatment, 
alternative treatment options for opioid users are available 
in all European countries. In the nine countries for which 
data are available, between 2 % and 30 % of all opioid 
users in treatment receive interventions not involving 
opioid substitution (Figure 3.7). 
 Methadone is the most  
 commonly prescribed  
 opioid substitution drug 
Buprenorphine
Methadone
Both drugs equally 
prescribed
FIGURE 3.6
Principal opioid substitution drug prescribed
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I Matching treatment provision to client needs
Clients accessing treatment services in Europe have 
differing needs and often require interventions that have to 
address a complex range of problems. Ensuring 
cooperation between drug services and other health and 
social providers is therefore a key component of an 
effective response in this area. 
As most of those entering drug treatment will be using 
more than one psychoactive substance, and some will be 
experiencing problems with multiple substances, drug 
services assessment and treatment plans that address 
polydrug use are important. Some combinations of 
substances may be particularly important to identify 
because of the high risk they pose — including a greater 
risk of overdose. One example is the use of opioids in 
combination with benzodiazepines. Analysis shows that 
three-quarters of clients entering treatment for problems 
related to their drug use are formally recorded as using 
multiple substances with primary opioid, cocaine and 
amphetamine users most frequently reporting cannabis 
and alcohol as secondary drugs. In addition, many primary 
opioid users also report the secondary use of cocaine.
Comorbidity of substance use and mental health disorders 
refers to the co-occurrence of the two clinical conditions in 
the same individual. There is also an association between 
some mental health disorders and substance use 
disorders. Thus, comorbidity is a challenge for both drug 
and mental health services. In a recent review, the most 
frequently identified psychiatric comorbidities among 
users of illicit substances were major depression, anxiety 
disorders (mainly panic and post-traumatic stress 
disorders) and personality disorders (mainly antisocial and 
borderline). Despite the importance of this issue, 
establishing the extent of the problem is difficult, as the 
data available are both limited and heterogeneous. 
There are indications that women in drug treatment may 
have more complex needs, particularly in relation to 
comorbidity and childcare responsibilities, and require 
more targeted and gender-sensitive services. While overall 
women represent only 20 % of specialised treatment 
entrants (i.e. male to female ratio of 4:1), this difference 
varies by country, ranging from 5 % to 34 %, and is less 
marked among first-time entrants. The reasons for lower 
numbers of women entering drug treatment are various, 
and may include differences between the sexes in the 
prevalence of problem use, the likelihood of reporting 
problem use, and issues of access and appropriateness of 
service provision.
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I HIV outbreaks: stimulant injectors 
Drug users, and particularly those who inject drugs, are at 
risk of contracting infectious diseases through the sharing 
of drug use material and through unprotected sex. Drug 
injection continues to play a central role in the 
transmission of blood-borne infections such as the 
hepatitis C virus (HCV) and, in some countries, the human 
immunodeficiency virus (HIV). Among all HIV cases notified 
in Europe where the route of transmission is known, the 
percentage attributable to injecting drug use remains low 
and stable (under 8 % for the last decade). Higher rates, 
however, were reported for Lithuania (32 %), Latvia (31 %), 
Estonia (28 %) and Romania (25 %).
The latest data show that the long-term decline in the 
number of new HIV diagnoses among injectors in the 
European Union continues. In 2014, the average rate of 
newly reported HIV diagnoses attributed to injecting drug 
use was 2.4 per million population, which is less than half 
that for 2005 (5.6 per million). Higher rates, however, were 
reported in a number of countries, particularly Estonia and 
Latvia. In Greece and Romania, countries that have 
previously experienced local outbreaks, rates of newly 
reported diagnoses have declined since 2012 (Figure 3.8). 
There were 1 236 newly reported drug injection-related HIV 
diagnoses in the European Union in 2014, the lowest 
number reported for more than a decade. Nevertheless, 
localised outbreaks in new HIV infections among people 
who inject drugs have been documented in Ireland, the 
United Kingdom (Scotland) and Luxembourg in 2015. 
Changes in drug use patterns, particularly increased 
stimulant injection, and high levels of marginalisation have 
been common factors in a number of these recent HIV 
outbreaks.
In 2014, 15 % of new AIDS cases in Europe were attributed 
to injecting drug use, with the 590 notifications 
representing just over a quarter of the number reported a 
decade ago. Early diagnosis is crucial in preventing 
progression from HIV infection to AIDS, and this is 
particularly relevant in relation to drug injectors, who are 
the transmission group with the highest share presenting 
to health services at a late stage of infection (61 %). 
Moreover, in some countries such as Greece, Latvia and 
Romania, where the numbers of new AIDS diagnoses 
remain at high levels, HIV testing and treatment responses 
may require strengthening. 
FIGURE 3.8
Newly diagnosed HIV cases related to injecting drug use: overall and selected trends and most recent data
<5.1 5.1–10.0 >10.0Cases per million population
NB: Data for 2014 (source: ECDC).
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I High HCV prevalence among injectors
Viral hepatitis, particularly infection caused by the hepatitis 
C virus (HCV), is highly prevalent among injecting drug 
users across Europe. This may have important long-term 
consequences, as HCV infection, often worsened by heavy 
alcohol use, is likely to account for increasing numbers of 
cases of liver disease, including cirrhosis and liver cancer, 
among an ageing population of high-risk drug users. 
The prevalence of antibodies to HCV, indicating present or 
past infection, among national samples of injecting drug 
users in 2013–14 varied from 15 % to 84 %, with 6 of the 
13 countries with national data reporting rates in excess of 
50 % (Figure 3.9). Among countries with national trend 
data for the period 2006–14, five countries observed an 
increasing trend in HCV-antibody prevalence in injecting 
drug users, while Malta and Norway observed a decrease. 
Drug injection is a risk factor for other infectious diseases 
including hepatitis B, tetanus and botulism. Clusters and 
sporadic cases of wound botulism among injecting drug 
users have been reported in Europe, including in Norway 
and the United Kingdom between 2013 and 2015. 
Bacterial injection site infections are also common, with a 
large outbreak of soft tissue infections reported in 
Scotland in 2015.
FIGURE 3.9
HCV antibody prevalence among injecting drug users, 2013/14
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I Infectious diseases: prevention measures
The main approaches taken to reduce drug-related 
infectious diseases among people who inject drugs 
include provision of opioid substitution treatment, 
provision of injecting equipment, testing, hepatitis C 
treatment and antiretroviral treatment for HIV. 
For injecting opioid users, being in substitution treatment 
significantly lowers infection risk, with some analyses 
indicating increasing protective effects when high 
treatment coverage is combined with high levels of syringe 
provision. 
Evidence shows that needle and syringe programmes can 
reduce injecting risk behaviour and may therefore reduce 
the transmission of HIV among people who inject drugs. 
Almost all countries provide clean injecting equipment at 
specialised outlets free of charge. However, the 
geographical distribution of syringe outlets as well as the 
estimates of numbers of syringes given out varies 
considerably between countries (Figure 3.10). Information 
on the provision of syringes through specialised 
programmes is available from 23 countries, which together 
report the distribution of around 36 million syringes in 
2014. This number is an underestimate, as several large 
countries, such as France, Germany, Italy and the United 
Kingdom, do not report full national data on syringe 
provision.
Testing for and treatment of infectious diseases can help 
to reduce incidence and prevalence of infections among 
drug users. Testing can both increase individual awareness 
of infection status and support earlier treatment uptake. 
However, stigma and marginalisation as well as limited 
knowledge about screening and treatment options remain 
barriers to uptake. Clinical data support the initiation of 
antiretroviral treatment immediately after diagnosis of HIV 
infection, in order to prevent any further decline of immune 
function. 
Targeted harm reduction and sexual health interventions 
are also important when addressing the new patterns of 
injecting and sexual behaviours reported among small 
groups of men who have sex with men. Establishing links 
between drug and sexual health services may be 
particularly important alongside provision of health 
education, sterile injecting equipment and, in some cases, 
pre-exposure prophylaxis with antiretroviral drugs. 
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Number of syringes provided through specialised programmes per injecting drug user (estimate)
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I Hepatitis C: new treatments
Prevention measures targeting the transmission of the 
hepatitis C virus are similar to those for HIV. As HCV 
infection is highly prevalent among people who inject 
drugs, reducing the number of people who can transmit 
the infection, by offering HCV treatment, is an essential 
component of a comprehensive prevention response. New 
European guidelines recommend providing HCV treatment 
to drug users on an individualised basis and delivering it in 
a multidisciplinary setting. Since 2013, all-oral, interferon-
free regimens with direct-acting antiviral agents have been 
available and are becoming the mainstay of the treatment 
of HCV infection. These medicines are highly effective, 
require shorter treatment time and have fewer side-effects 
than older medicines. Furthermore, treatment with these 
medicines may be offered in specialised drug services in 
community settings, which may increase uptake and 
availability.
The new anti-HCV medicines are expensive compared with 
the older medicines. In a survey of 21 EU countries in 
2015, the EMCDDA found that the average reference cost 
of three months’ treatment with a new medicine was 
around EUR 60 000, whereas treatment with medicines 
from the previous generation cost between EUR 17 000 
and EUR 26 000. Considering the high prevalence of HCV 
infection among injecting drug users, ensuring optimum 
access to promising new medicines continues to be a key 
challenge for policymakers.
I Prison health: comprehensive response needed
Prisoners report higher lifetime rates of drug use than the 
general population and more harmful patterns of use, 
illustrated by recent studies showing that between 6 % and 
48 % of prisoners have ever injected drugs. The high 
lifetime prevalence of drug use makes prisoners a 
population with complex healthcare needs, and a thorough 
health assessment upon prison entry is an important 
intervention. The WHO recommends a package of 
prevention responses for prisons, including free and 
voluntary testing for infectious diseases, distribution of 
condoms and sterile injecting equipment, infectious 
diseases treatment and treatment of drug dependence. 
Many countries have interagency partnerships between 
prison health services and providers in the community, 
which ensure delivery of health education and treatment 
interventions in prison and continuity of care upon prison 
entry and release. The availability of opioid substitution 
treatment in prisons is reported by 27 of the 30 countries 
monitored by the EMCDDA. Overall, it appears that 
substitution treatment is available to a growing share of 
the prison population, increasingly reflecting its 
widespread availability in the community. The provision of 
clean injecting equipment is less common, with only three 
countries reporting the existence of syringe programmes in 
this setting. 
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I Hospital emergencies: a window on acute harms
A unique insight into acute health harms is provided by 
hospital emergency data. A 2014 analysis by the European 
Drug Emergencies Network (Euro-DEN), which monitors 
drug-related emergency presentations in 16 selected 
(sentinel) hospitals in 10 European countries, found that 
most of the 5 409 presentations reported were in males 
(76 %) and young adults (median age 32 years for males 
and 28 years for females). Heroin was reported in 24 % of 
the presentations, cocaine in 17 % and cannabis in 16 %. 
In many of the presentations, more than one drug was 
found, with 8 358 drug identifications among the 5 409 
presentations (Figure 3.11). Two-thirds of presentations 
involved the use of established drugs such as heroin, 
cocaine, cannabis, amphetamine and MDMA; one quarter 
involved prescription or over the counter drugs (most 
commonly opioids and benzodiazepines); and 6 % involved 
new psychoactive substances. Heroin was the most 
commonly reported drug overall and the most commonly 
reported opioid (67 % of reported opioids), followed by 
methadone (12 %) and buprenorphine (5 %), with patterns 
varying between sites. Over three-quarters of the new 
psychoactive substance presentations involved a 
cathinone and two-thirds of these involved mephedrone. 
The drugs involved in emergency presentations differed 
between sites, reflecting local patterns of risky drug use. 
For example, emergencies related to heroin and 
amphetamine were the most common presentations in 
Oslo, whereas presentations related to GHB/GBL, cocaine, 
mephedrone and MDMA were predominant in London, 
mirroring the local patterns of use associated with 
recreational nightlife settings.
The majority (79 %) of those presenting with a drug-related 
problem were discharged from hospital within 12 hours. In 
total, 27 deaths were recorded (0.5 % of all presentations), 
most of which involved opioids.
Few countries have national monitoring systems in place 
that allow an analysis of trends in drug-related acute 
intoxications. Of the countries with longer term monitoring, 
reports show acute heroin emergencies are increasing in 
the United Kingdom, while decreasing in the Czech 
Republic and Denmark. These latter two countries have 
reported an increase in the number of emergencies related 
to other opioids. A continued increase in acute 
emergencies related to cannabis has been observed in 
Spain, while the Netherlands reports increases in MDMA 
intoxications presenting at first aid stations at festivals, 
and in acute intoxications related to the new psychoactive 
substance 4-FA (4-fluoroamphetamine).
Drug identications
NB: Results from 5 409 emergency presentations in 16 sentinel sites in 
10 European countries.
Source: European Drug Emergencies Network (Euro-DEN).
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Top 10 drugs recorded in emergency presentations to sentinel 
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I New drugs: health challenges
New substances have been associated with a range of 
serious harms in Europe including acute poisonings and 
deaths. There are also harms associated with patterns of 
drug injection, in particular with stimulants such as 
mephedrone, alpha-PVP, MDPV and pentedrone. Mass 
poisonings, although rare, can place heavy demands on 
healthcare systems. In one such incident, reported in 
Poland in 2015, synthetic cannabinoids were linked to over 
200 hospital emergency presentations in less than a week. 
Since early 2014, serious harms associated with the use of 
a new substance have led to 34 public health alerts being 
issued by the EMCDDA to members of the EU Early 
Warning System. Over this period, seven new substances 
were risk-assessed. Most recently, concerns have arisen 
around new opioids such as acetylfentanyl, which was 
subject to an EMCDDA–Europol joint report in 2015, after 
being associated with 32 deaths. Many fentanyls are highly 
potent, and may be sold as heroin to unsuspecting users, 
thus posing a high risk of overdose and death.
I Responding to new drugs: key interventions 
In general, existing prevention, treatment and harm 
reduction interventions for problems associated with 
established drugs are reported to be adequate for, or could 
be easily adapted to, the needs of users of new drugs. 
However, problems associated with the use of new 
psychoactive substances and other drugs such as GHB, 
ketamine and mephedrone, pose specific challenges in a 
number of settings, such as prisons, sexual health clinics 
and low-threshold drug services. Reports of challenges 
encountered in delivering interventions targeting these 
substances include accessing hard to reach drug-using 
populations (e.g. men who have sex with men), managing 
chaotic injecting behaviours among vulnerable groups, and 
supporting acute psychotic episodes linked with use of 
new drugs among prisoners. In these particular cases, the 
development of interventions that focus specifically on use 
of new drugs and related health harms are important, 
including for example, targeted harm reduction material 
and advice, and specialised treatment guidelines. 
Risk assessment of alpha-PVP
 
In November 2015, a European-level risk assessment was 
conducted on alpha-PVP (alpha-pyrrolidinopentiophenone). 
Alpha-PVP is a synthetic cathinone and a potent psychostimulant, 
and is similar to MDPV. It has been available on the drug market in 
the European Union since at least February 2011 and has been 
detected in all 28 Member States. Alpha-PVP was detected in 191 
acute intoxications and 115 deaths. In 20 % of the deaths, alpha-
PVP was reported as either the cause of death or a contributor to 
the death; in five of these cases, alpha-PVP was the only substance 
detected.
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I Overdose deaths: recent increases 
Drug use is a recognised cause of avoidable mortality 
among European adults. Studies on cohorts of high-risk 
drug users commonly show overall mortality rates in the 
range of 1–2 % per year. Overall, opioid users in Europe are 
5 to 10 times more likely to die than their peers of the 
same age and gender. Increased mortality among opioid 
users is primarily related to overdose, but other causes of 
death indirectly related to drug use, such as infections, 
accidents, violence and suicide, are also important.
In Europe, drug overdose continues to be the main cause 
of death among drug users, and over three-quarters of 
overdose victims are male (78 %). Most EU countries 
reported an increasing trend in overdose deaths from 2003 
until around 2008/09, when overall levels first began to 
decline. Caution is required when interpreting overdose 
data, and especially the EU cumulative total, for reasons 
which include systematic under-reporting in some 
countries and registration processes that result in 
reporting delays. Annual estimates therefore represent a 
provisional minimum value. For 2014, it is estimated that 
at least 6 800 overdose deaths occurred in the European 
Union. This represents an increase from the revised 2013 
figure and, as in previous years, the United Kingdom (36 %) 
and Germany (15 %) together account for a large part of 
the total. Increases are evident in the most recent data 
from a number of countries with relatively robust reporting 
systems, including Ireland, Lithuania and the United 
Kingdom. A marked upward trend is also observed in 
Sweden, though it may be partly due to the inclusion of 
some cases aged 50 and over not related to illicit drug use. 
Turkey is also showing large increases, but this may partly 
reflect improved reporting practices. 
Reflecting the ageing nature of Europe’s opioid-using 
population, who are at greatest risk of drug overdose 
death, the reported number of overdose deaths increased 
among older age groups between 2006 and 2014, while 
those among younger age groups decreased. However, 
there has recently been a slight increase in the number of 
overdose deaths reported among those aged under 25 in 
some countries.
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Heroin or its metabolites are present in the majority of fatal 
overdoses reported in Europe, often in combination with 
other substances. Other opioids including methadone, 
buprenorphine, fentanyls and tramadol are also regularly 
found in toxicological reports, and these substances are 
associated with a substantial share of overdose deaths in 
some countries. In the United Kingdom (England and 
Wales) for example, out of the 1 786 deaths registered in 
2014 where opioids were mentioned, methadone was 
recorded in 394 and tramadol in 240. Among the other 
countries reporting the occurrence of opioids other than 
heroin in fatal overdoses are France and Ireland (mainly 
methadone), and Finland, where buprenorphine was 
mentioned in 75 cases in 2014. 
Stimulants such as cocaine, amphetamines, MDMA and 
cathinones are implicated in a smaller number of overdose 
deaths in Europe, although their significance varies by 
country. In the United Kingdom (England and Wales), 
deaths involving cocaine increased from 169 in 2013 to 
247 in 2014. In Spain, where cocaine-related deaths have 
been stable for some years, the drug continued to be the 
second most often cited drug in overdose deaths in 2013 
(236 cases). 
I Mortality rates highest in northern Europe
For 2014, the mortality rate due to overdoses in Europe is 
estimated at 18.3 deaths per million population aged 
15–64. National mortality rates vary considerably and are 
influenced by factors such as prevalence and patterns of 
drug use and methodological issues such as under-
reporting and coding practices. Rates of over 40 deaths 
per million were reported in 8 countries, with the highest 
rates reported in Estonia (113 per million), Sweden (93 per 
million) and Ireland (71 per million) (Figure 3.12). The most 
recent data show varying trends.
FIGURE 3.12
Drug-induced mortality rates among adults (15–64): selected trends and most recent data
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I Preventing overdoses and drug-related deaths 
Reducing fatal drug overdoses and other drug-related 
deaths is a major public health challenge in Europe. 
Targeted responses in this area focus either on preventing 
the occurrence of overdoses, or on improving the likelihood 
of surviving an overdose. Drug treatment, particularly 
opioid substitution treatment, prevents overdoses and 
reduces the mortality risk of drug users in treatment. 
Supervised drug consumption facilities aim both to 
prevent overdoses from happening and to ensure 
professional support is available if an overdose occurs. 
Six countries currently provide such facilities — around 
70 in total.
Naloxone is an opioid antagonist medication that can 
reverse opioid overdose and is used in hospital emergency 
departments and by ambulance personnel. In recent years, 
there has been a growth in the provision of ‘take-home’ 
naloxone to opioid users, their partners, peers and families, 
alongside training in recognising and responding to 
overdose. Naloxone has also been made available for use 
by staff of services that regularly come into contact with 
drug users. A recent European review found that take-
home naloxone programmes exist in eight European 
countries. Naloxone kits are generally provided by drug and 
health services in the form of pre-filled syringes, although 
in Norway and Denmark an adaptor allows naloxone to be 
administered intra-nasally. A recent systematic review of 
the effectiveness of take-home naloxone found evidence 
that educational and training interventions with provision 
of take-home naloxone decrease overdose-related 
mortality. Some populations with an elevated risk of 
overdose, such as recently released prisoners, may 
particularly benefit. A recent Scottish evaluation of the 
national naloxone programme found that it was associated 
with a 36 % reduction in the proportion of opioid-related 
deaths that occurred within a month of prison release.
I Demand reduction services: quality standards
As demand reduction services have become widespread, 
increasing focus has been placed on service quality, 
culminating in the adoption of ‘Minimum quality standards 
in drug demand reduction in the European Union’ by the 
EU Council of Ministers in September 2015. Sixteen 
standards for prevention, treatment, harm reduction and 
social reintegration set minimum quality benchmarks for 
interventions. The newly adopted standards represent a 
major development in the drugs field at EU level, bringing 
together expert knowledge and political decision-making 
across 28 countries. The standards reinforce the need to 
base interventions on evidence and to provide staff with 
appropriate training. They also facilitate the sharing of best 
practice at a European level and promote knowledge 
exchange.
I Understanding costs of drug-related actions
Understanding the costs of drug-related actions is an 
important aspect of policy evaluation. Nevertheless, the 
information available on drug-related public expenditure in 
Europe, at both local and national level, remains sparse 
and heterogeneous. For the 18 countries that have 
produced estimates in the past 10 years, drug-related 
public expenditure is estimated at between 0.01 % and 
0.5 % of gross domestic product (GDP), with health 
interventions representing between 15 % and 53 % of all 
drug-related public expenditure. 
A recent exercise estimated that the provision of inpatient 
treatment for drug-related health problems in hospitals 
represented, on average, 0.013 % of GDP in the 15 
countries with available data. However, this proportion 
differed considerably across countries. To provide a more 
comprehensive estimate of the costs of treating drug-
related health problems in hospitals, more systematic 
recording of emergency presentations would be required.
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Annex: national data tables
OPIOIDS
High-risk opioid use 
estimate
Entrants into treatment during the year
Clients in 
substitution 
treatment
Opioids clients as % of treatment entrants % opioids clients injecting (main route of administration)
All entrants First-time entrants
Previously 
treated 
entrants
All entrants First-time entrants
Previously 
treated 
entrants
Country Year of estimate
cases per 
1 000 % (count) % (count) % (count) % (count) % (count) % (count) count
Belgium – – 28.9 (3 079) 11.5 (434) 37.5 (2 352) 18.4 (541) 12 (51) 19.3 (431) 17 026
Bulgaria – – 84.8 (1 530) 64.5 (207) 96 (932) 73 (772) 69.9 (116) 75.5 (580) 3 414
Czech 
Republic
2014 1.4–1.8 17 (1 720) 7 (333) 25.9 (1 387) 82.6 (1 412) 79.8 (264) 83.2 (1 148) 4 000
Denmark – – 17.5 (663) 7.1 (102) 26.3 (502) 33.9 (193) 23 (20) – 2 600
Germany 2013 2.7–3.2 34.9 (29 655) 13.1 (3 304) 44 (26 351) 34.1 (11 225) 32.2 (1 460) 34.4 (9 765) 77 500
Estonia – – 90 (253) 89.5 (51) 97.3 (179) 78.8 (197) 64.7 (33) 83.2 (149) 919
Ireland – – 49.8 (4 745) 27.5 (1 036) 65.5 (3 456) 42.2 (1 908) 35.7 (362) 43.6 (1 441) 9 764
Greece 2014 2.1–2.8 69.2 (3 250) 55.3 (1 060) 78.9 (2 176) 33.4 (1 078) 27.7 (291) 36.3 (786) 10 226
Spain 2013 1.6–2.5 24.8 (12 863) 10.9 (3 066) 42.1 (9 515) 15.8 (1 916) 9.9 (282) 17.7 (1 608) 61 954
France 2013–14 4.4–7.4 30.5 (12 634) 13.8 (1 240) 44.5 (8 662) 19.9 (2 119) 13.8 (155) 22 (1 620) 161 388
Croatia 2010 3.2–4 79.9 (6 241) 19.9 (210) 89 (5 516) 73.3 (4 529) 44.9 (88) 74.3 (4 063) 6 867
Italy 2014 4.6–5.8 56 (28 671) 40.6 (7 416) 64.5 (21 255) 47.2 (13 209) 45.9 (2 992) 58.4 (10 217) 75 964
Cyprus 2014 1.5–2.4 25.4 (271) 11.5 (65) 42.2 (204) 56.8 (154) 50.8 (33) 59.3 (121) 178
Latvia 2014 3.4–7.5 46.2 (382) 24.7 (102) 67.8 (280) 91 (343) 87.1 (88) 92.4 (255) 518
Lithuania 2007 2.3–2.4 88.2 (1 905) 66.6 (227) 92.6 (1 665) 84.4 (1 607) 84.6 (192) 84.3 (1 402) 585
Luxembourg 2007 5–7.6 53.9 (146) 46.4 (13) 51 (100) 50.3 (72) 15.4 (2) 52 (51) 1 121
Hungary 2010–11 0.4–0.5 4.2 (196) 1.6 (51) 9.5 (118) 60.2 (109) 55.1 (27) 63.5 (73) 745
Malta 2014 5.3–6.2 72.8 (1 277) 27.5 (58) 79 (1 219) 63.4 (786) 47.3 (26) 64.1 (760) 1 013
Netherlands 2012 1.1–1.5 10.5 (1 113) 5.7 (346) 16.9 (767) 6.5 (44) 9.3 (18) 5.4 (26) 7 569
Austria 2013 4.9–5.1 50.8 (1 737) 29.2 (435) 67.3 (1 302) 35.9 (479) 23.1 (79) 40.3 (400) 17 272
Poland 2009 0.4–0.7 14.8 (1 061) 4.7 (162) 25 (877) 61.5 (632) 39.1 (61) 65.1 (555) 2 586
Portugal 2012 4.2–5.5 53.8 (1 538) 26.3 (357) 78.8 (1 180) 18.3 (255) 12.5 (39) 19.9 (216) 16 587
Romania – – 41.8 (1 094) 15.1 (211) 74 (852) 92.4 (1 007) 85.7 (180) 94 (799) 593
Slovenia 2013 3.4–4.1 75.9 (318) 55.5 (61) 83.1 (250) 32.3 (101) 20.7 (12) 35.7 (89) 3 190
Slovakia 2008 1–2.5 21.9 (543) 12.7 (147) 30.5 (387) 71.2 (376) 55.9 (81) 76.8 (288) 375
Finland 2012 3.8–4.5 57.8 (372) 41.9 (111) 68.9 (261) 79.1 (291) 68.2 (75) 83.7 (216) 3 000
Sweden – – 24.7 (7 737) 14.7 (1 680) 30.2 (5 838) 62.1 (175) 20 (4) 47.4 (27) 3 502
United 
Kingdom
2010–11 7.9–8.4 52.1 (50 592) 23.2 (7 911) 68 (42 045) 33.3 (15 380) 20.8 (1 217) 35 (13 892) 148 868
Turkey 2011 0.2–0.5 70.3 (7 476) 61.1 (3 420) 80.6 (4 056) 30 (2 243) 20.5 (702) 38 (1 541) 28 656
Norway 2013 2–4.2 23 (1 974) – – – – – 7 433
European 
Union
– – 39.2 (175 586) 18.6 (30 396) 52.6 (139 628) 37.8 (60 910) 31.4 (8 248) 40.4 (50 978) 644 324
EU, Turkey 
and Norway
– – 39.6 (185 036) 20.0 (33 816) 53.2 (143 684) 37.4 (63 153) 30.2 (8 950) 40.3 (52 519) 680 413
Data on clients in substitution treatment are for 2014, or most recent year available: Denmark and Finland, 2011; Turkey, 2012; Spain and Malta, 2013; data for 
Ireland are based on a census taken on 31 December 2013.
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COCAINE
Prevalence estimates Entrants into treatment during the year
General population School population Cocaine clients as % of treatment entrants
% cocaine clients injecting 
(main route of administration)
Year of 
survey
Lifetime, 
adults 
(15–64) 
Last 12 
months, 
young 
adults 
(15–34)
Lifetime, 
students 
(15–16)
All entrants First-time entrants
Previously 
treated 
entrants
All clients
First-
time 
entrants
Previously 
treated 
entrants
Country % % % % (count) % (count) % (count) % (count) % (count) % (count)
Belgium 2013 – 0.9 2 17 (1 809) 16.7 (628) 16.9 (1 058) 4.9 (84) 1.2 (7) 6.1 (60)
Bulgaria 2012 0.9 0.3 4 1.6 (29) 6.5 (21) 0.8 (8) 7.1 (2) 0 (0) 25 (2)
Czech 
Republic
2014 0.9 0.6 1 0.3 (27) 0.3 (12) 0.3 (15) 0 (0) 0 (0) 0 (0)
Denmark 2013 5.2 2.4 2 5.1 (193) 5.8 (84) 5.2 (99) 10.1 (17) 0 (0) –
Germany 2012 3.4 1.6 3 5.9 (4 978) 5.3 (1 340) 6.1 (3 638) 16.9 (2 650) 7.8 (292) 19.8 (2 358)
Estonia 2008 – 1.3 2 0.4 (1) – – – – –
Ireland 2011 6.8 2.8 3 8.7 (828) 11.2 (424) 6.8 (358) 1.4 (11) 0.5 (2) 2.6 (9)
Greece 2004 0.7 0.2 1 5.1 (239) 5.2 (100) 5 (139) 14.7 (35) 6 (6) 21 (29)
Spain 2013 10.3 3.3 3 38.2 (19 848) 38 (10 734) 38.6 (8 726) 2.3 (426) 1.2 (128) 3.5 (291)
France 2014 5.4 2.4 4 6.1 (2 530) 5.4 (489) 7.7 (1 508) 9.9 (224) 2.6 (12) 13.7 (186)
Croatia 2012 2.3 0.9 2 1.7 (132) 3.1 (33) 1.5 (90) 3.1 (4) 3.4 (1) 3.3 (3)
Italy 2014 7.6 1.8 2 23.7 (12 165) 27.4 (5 006) 21.7 (7 159) 6.2 (739) 4.7 (227) 7.4 (512)
Cyprus 2012 1.3 0.6 4 10.3 (110) 7.1 (40) 14.1 (68) 9.2 (10) 7.5 (3) 10.4 (7)
Latvia 2011 1.5 0.3 4 0.7 (6) 1.2 (5) 0.2 (1) 0 (0) 0 (0) 0 (0)
Lithuania 2012 0.9 0.3 2 0.2 (5) 0.3 (1) 0.2 (4) 20 (1) 0 (0) 25 (1)
Luxembourg – – – – 19.9 (54) 25 (7) 18.4 (36) 34.7 (17) 50 (3) 31.4 (11)
Hungary 2007 0.9 0.4 2 1.8 (86) 1.9 (59) 1.9 (23) 5.9 (5) 1.7 (1) 17.4 (4)
Malta 2013 0.5 – 4 15.9 (279) 40.3 (85) 12.6 (194) 21.9 (60) 9.4 (8) 27.5 (52)
Netherlands 2014 5.1 3.0 2 26.3 (2 791) 22 (1 344) 31.9 (1 447) 0.2 (4) 0.1 (1) 0.3 (3)
Austria 2008 2.2 1.2 – 8.4 (288) 9.7 (145) 7.4 (143) 4.2 (10) 1.6 (2) 7.2 (8)
Poland 2014 1.3 0.4 3 1.4 (98) 1.3 (44) 1.5 (51) 1.1 (1) 0 (0) 2.1 (1)
Portugal 2012 1.2 0.4 4 13.5 (385) 17.5 (237) 9.8 (147) 5.7 (20) 2.8 (6) 10.4 (14)
Romania 2013 0.8 0.2 2 0.8 (21) 1.1 (15) 0.5 (6) 0 (0) 0 (0) 0 (0)
Slovenia 2012 2.1 1.2 3 6 (25) 5.5 (6) 6.3 (19) 62.5 (15) 16.7 (1) 77.8 (14)
Slovakia 2010 0.6 0.4 1 0.9 (23) 1.4 (16) 0.6 (7) 4.3 (1) 6.3 (1) 0 (0)
Finland 2014 1.9 1.0 1 0 (0) 0 (0) 0 (0) – – –
Sweden 2008 3.3 1.2 1 0.9 (284) 1.6 (189) 0.5 (87) 3.1 (1) 0 (0) 0 (0)
United 
Kingdom (1)
2014 9.8 4.2 2 12.6 (12 236) 16.9 (5 752) 10.4 (6 399) 1.4 (161) 0.3 (16) 2.3 (144)
Turkey – – – – 1.3 (134) 1.2 (66) 1.4 (68) – – –
Norway 2014 5.0 2.3 1 1 (84) – – – – –
European 
Union
– 5.1 1.9 – 13.3 (59 470) 16.4 (26 816) 11.8 (31 430) 6.7 (4 498) 2.6 (717) 9.8 (3 709)
EU, Turkey 
and Norway
– – – – 12.8 (59 688) 15.9 (26 882) 11.6 (31 498) 6.7 (4 498) 2.6 (717) 9.7 (3 709)
Prevalence estimates for the school population are taken from national school surveys or the ESPAD project.
(1) Prevalence estimates for the general population refer to England and Wales only.
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AMPHETAMINES
Prevalence estimates Entrants into treatment during the year
General population School population
Amphetamines clients as % of treatment 
entrants
% amphetamines clients injecting 
(main route of administration)
Year of 
survey
Lifetime, 
adults 
(15–64)
Last 12 
months, 
young 
adults 
(15–34)
Lifetime, 
students 
(15–16)
All entrants First-time entrants
Previously 
treated 
entrants
All entrants First-time entrants
Previously 
treated 
entrants
Country % % % % (count) % (count) % (count) % (count) % (count) % (count)
Belgium 2013 – 0.5 2 9.8 (1 047) 9.4 (353) 10.7 (669) 12.6 (128) 5.3 (18) –
Bulgaria 2012 1.2 1.3 5 4.7 (84) 15.9 (51) 1.6 (16) 2 (1) 0 (0) 0 (0)
Czech 
Republic
2014 2.6 2.3 2 69.7 (7 033) 75.1 (3 550) 65 (3 483) 78.1 (5 446) 73.8 (2 586) 82.6 (2 860)
Denmark 2013 6.6 1.4 2 9.5 (358) 10.3 (149) 8.9 (170) 3.1 (9) 0 (0) –
Germany 2012 3.1 1.8 4 16.1 (13 664) 19.3 (4 860) 14.7 (8 804) 1.5 (277) 0.9 (55) 1.8 (222)
Estonia 2008 – 2.5 3 3.9 (11) 3.5 (2) 1.6 (3) 72.7 (8) 100 (2) 66.7 (2)
Ireland 2011 4.5 0.8 2 0.6 (55) 0.8 (30) 0.5 (24) 5.5 (3) 3.3 (1) 8.3 (2)
Greece 2004 0.1 0.1 2 0.4 (18) 0.7 (13) 0.2 (5) 22.2 (4) 30.8 (4) 0 (0)
Spain 2013 3.8 1.2 1 1.3 (671) 1.4 (391) 1.2 (261) 1.2 (8) 0.8 (3) 1.6 (4)
France 2014 2.2 0.7 4 0.6 (232) 0.7 (66) 0.5 (96) 8.2 (16) 9.7 (6) 11.4 (9)
Croatia 2012 2.6 1.6 1 1.2 (96) 2.7 (28) 1 (65) 0 (0) 0 (0) 0 (0)
Italy 2014 2.8 0.6 1 0.2 (83) 0.3 (57) 0.1 (26) 6.1 (5) 7.1 (4) 4.3 (1)
Cyprus 2012 0.7 0.4 4 4.3 (46) 3.5 (20) 5.4 (26) 4.3 (2) 5 (1) 3.8 (1)
Latvia 2011 2.2 0.6 4 13.9 (115) 15 (62) 12.8 (53) 63.1 (70) 66.7 (40) 58.8 (30)
Lithuania 2012 1.2 0.5 3 3.4 (73) 8.2 (28) 2.3 (42) 32.9 (24) 32.1 (9) 35.7 (15)
Luxembourg – – – – – – – – – –
Hungary 2007 1.8 1.2 6 12.5 (584) 12.3 (383) 12.4 (154) 13 (74) 9.6 (36) 22.2 (34)
Malta 2013 0.3 – 3 0.2 (4) – 0.3 (4) 25 (1) – 25 (1)
Netherlands 2014 4.4 2.9 1 6.6 (702) 6.2 (376) 7.2 (326) 0.8 (3) 0 (0) 1.8 (3)
Austria 2008 2.5 0.9 – 4.6 (157) 5.9 (88) 3.6 (69) 5.3 (7) 5.2 (4) 5.4 (3)
Poland 2014 1.7 0.4 4 28.1 (2 019) 27.7 (956) 29.5 (1 036) 4.8 (91) 2.3 (21) 7.5 (70)
Portugal 2012 0.5 0.1 3 0 (1) 0.1 (1) 0 (0) – 0 (0) –
Romania 2013 0.3 0.1 2 0.2 (4) 0.2 (3) 0.1 (1) 25 (1) 0 (0) 100 (1)
Slovenia 2012 0.9 0.8 2 0.5 (2) – 0.7 (2) – – –
Slovakia 2010 0.5 0.3 1 42.7 (1 060) 47.8 (553) 38.9 (493) 32.8 (337) 26.1 (140) 40.3 (194)
Finland 2014 3.4 2.4 – 12.1 (78) 13.2 (35) 11.3 (43) 84.2 (64) 80 (28) 87.8 (36)
Sweden 2008 5 1.3 1 0.5 (141) – – – – –
United 
Kingdom (1)
2014 10.3 1.1 1 2.9 (2 830) 3.7 (1 250) 2.5 (1 540) 21.6 (464) 12.2 (101) 27.6 (354)
Turkey 2011 0.1 0.1 2 0.3 (27) 0.4 (21) 0.1 (6) – – –
Norway (2) 2014 4.1 1.1 1 13.4 (1 147) – – – – –
European 
Union
– 3.6 1 – 7 (31 168) 8.2 (13 305) 6.6 (17 411) 20.8 (7 139) 22.5 (3 059) 19.7 (3 950)
EU, Turkey 
and Norway
– – – – 6.9 (32 342) 7.9 (13 326) 6.5 (17 417) 20.8 (7 139) 22.4 (3 059) 19.7 (3 950)
Amphetamines refers to both amphetamine and methamphetamine.
Prevalence estimates for the school population are taken from national school surveys or the ESPAD project.
(1) Prevalence estimates for the general population refer to England and Wales only.
(2) Entrants into treatment refer to clients reporting stimulants other than cocaine, not just amphetamines.
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MDMA
Prevalence estimates Entrants into treatment during the year
General population School population MDMA clients as % of treatment entrants
Year of survey
Lifetime, 
adults 
(15–64)
Last 12 
months, 
young adults 
(15–34)
Lifetime, 
students 
(15–16)
All entrants First-time entrants
Previously 
treated 
entrants
Country % % % % (count) % (count) % (count)
Belgium 2013 – 0.8 2 0.6 (65) 0.9 (34) 0.5 (31)
Bulgaria 2012 2.0 2.9 4 0.2 (3) 0.6 (2) 0.1 (1)
Czech 
Republic
2014 6.0 3.6 3 0 (4) 0.1 (3) 0 (1)
Denmark 2013 2.3 0.7 1 0.3 (13) 0.5 (7) 0.3 (5)
Germany 2012 2.7 0.9 2 – – –
Estonia 2008 – 2.3 3 – – –
Ireland 2011 6.9 0.9 2 0.6 (56) 1 (37) 0.3 (18)
Greece 2004 0.4 0.4 2 0.1 (4) 0.1 (1) 0.1 (3)
Spain 2013 4.3 1.5 1 0.4 (201) 0.6 (167) 0.1 (27)
France 2014 4.2 2.3 3 0.4 (148) 0.6 (57) 0.3 (63)
Croatia 2012 2.5 0.5 2 0.4 (32) 1.3 (14) 0.3 (17)
Italy 2014 3.1 1.0 1 0.3 (147) 0.3 (48) 0.3 (99)
Cyprus 2012 0.9 0.3 3 0.1 (1) – 0.2 (1)
Latvia 2011 2.7 0.8 4 0.4 (3) 0.7 (3) 0 (0)
Lithuania 2012 1.3 0.3 2 0 (1) 0 (0) 0.1 (1)
Luxembourg – – – – – – –
Hungary 2007 2.4 1.0 4 1.7 (82) 1.8 (55) 1.9 (23)
Malta 2013 0.7 – 3 0.9 (16) – 1 (16)
Netherlands 2014 7.4 5.5 4 0.4 (45) 0.7 (40) 0.1 (5)
Austria 2008 2.3 1.0 0.8 (27) 1.3 (19) 0.4 (8)
Poland 2014 1.6 0.9 2 0.2 (11) 0.1 (5) 0.2 (6)
Portugal 2012 1.3 0.6 3 0.2 (5) 0.4 (5) 0 (0)
Romania 2013 0.9 0.3 2 0.5 (14) 1 (14) 0 (0)
Slovenia 2012 2.1 0.8 2 – – –
Slovakia 2010 1.9 0.9 1 0.1 (2) 0.1 (1) 0.1 (1)
Finland 2014 3.0 2.5 2 0.2 (1) 0 (0) 0.3 (1)
Sweden 2008 2.1 1.0 1 – – –
United 
Kingdom (1)
2014 9.2 3.5 3 0.3 (302) 0.6 (200) 0.2 (97) 
Turkey 2011 0.1 0.1 2 1 (103) 1.3 (74) 0.6 (29)
Norway 2014 2.3 0.4 1 – – –
European 
Union
– 3.9 1.7 – 0.3 (1 184) 0.4 (712) 0.2 (424)
EU, Turkey and 
Norway
– – – – 0.3 (1 287) 0.5 (786) 0.2 (453)
Prevalence estimates for the school population are taken from national school surveys or the ESPAD project.
(1) Prevalence estimates for the general population refer to England and Wales.
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CANNABIS
Prevalence estimates Entrants into treatment during the year
General population School population Cannabis clients as % of treatment entrants
Year of survey
Lifetime, 
adults 
(15–64)
Last 12 
months, 
young adults 
(15–34)
Lifetime, 
students 
(15–16)
All entrants First-time entrants
Previously 
treated 
entrants
Country % % % % (count) % (count) % (count)
Belgium 2013 15 10.1 21 32.9 (3 501) 52.8 (1 984) 22.4 (1 403)
Bulgaria 2012 7.5 8.3 22 3.2 (58) 8.4 (27) 0.7 (7)
Czech 
Republic
2014 28.7 23.9 42 11.8 (1 195) 16.4 (776) 7.8 (419)
Denmark 2013 35.6 17.6 18 63.4 (2 397) 72.6 (1 048) 55.5 (1 061)
Germany 2012 23.1 11.1 19 37.9 (32 225) 57.5 (14 458) 29.7 (17 767)
Estonia 2008 – 13.6 24 3.2 (9) 7 (4) 0.5 (1)
Ireland 2011 25.3 10.3 18 27.8 (2 645) 44.9 (1 696) 16 (847)
Greece 2004 8.9 3.2 8 22.3 (1 046) 36.5 (699) 12.3 (338)
Spain 2013 30.4 17.0 27 32.6 (16 914) 45.7 (12 912) 15.9 (3 585)
France 2014 40.9 22.1 39 58 (24 003) 76.7 (6 897) 42.3 (8 248)
Croatia 2012 15.6 10.5 18 14.1 (1 103) 64.4 (679) 6.5 (401)
Italy 2014 31.9 19.0 20 18.2 (9 321) 28.8 (5 267) 12.3 (4 054)
Cyprus 2012 9.9 4.2 7 59.4 (634) 77.2 (436) 37.7 (182)
Latvia 2011 12.5 7.3 24 32.6 (269) 50.8 (210) 14.3 (59)
Lithuania 2012 10.5 5.1 20 4.3 (92) 14.7 (50) 2.3 (42)
Luxembourg – – – – 25.5 (69) 28.6 (8) 29.6 (58)
Hungary 2007 8.5 5.7 19 55.5 (2 603) 61.2 (1 910) 43.2 (537)
Malta 2013 4.3 – 10 9 (158) 31.8 (67) 5.9 (91)
Netherlands 2014 24.1 15.6 27 47.6 (5 061) 56.2 (3 429) 36 (1 632)
Austria 2008 14.2 6.6 14 32.2 (1 101) 50.9 (757) 17.8 (344)
Poland 2014 16.2 9.8 23 34.6 (2 483) 44.6 (1 540) 25 (877)
Portugal 2012 9.4 5.1 16 28.4 (812) 50.8 (690) 8.1 (122)
Romania 2013 4.6 3.3 7 37.2 (973) 61.4 (858) 9 (104)
Slovenia 2012 15.8 10.3 23 12.2 (51) 36.4 (40) 3.3 (10)
Slovakia 2010 10.5 7.3 21 20.5 (509) 28.6 (331) 12.5 (159)
Finland 2014 21.7 13.5 12 20.5 (132) 35.1 (93) 10.3 (39)
Sweden 2014 14.4 6.3 6 13.2 (4 141) 20.7 (2 372) 8.9 (1 717)
United 
Kingdom (1)
2014 29.2 11.7 19 26 (25 278) 46.6 (15 895) 14.8 (9 137)
Turkey 2011 0.7 0.4 4 9 (955) 11.3 (634) 6.4 (321)
Norway 2014 21.9 8.6 5 22.7 (1 946) – –
European 
Union
– 24.8 13.3 – 31 (138 783) 46 (75 133) 20.1 (53 241)
EU, Turkey and 
Norway
– – – – 30.4 (141 684) 44.9 (75 767) 19.8 (53 562)
Prevalence estimates for the school population are taken from national school surveys or the ESPAD project.
(1) Prevalence estimates for the general population refer to England and Wales.
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OTHER INDICATORS
Drug-induced deaths 
(aged 15–64)
HIV diagnoses attributed 
to injecting drug use 
(ECDC)
Injecting drug use estimate
Syringes distributed 
through specialised 
programmes
Country cases per million population (count)
cases per million 
population (count)
Year of 
estimate
cases per 
1 000 
population
count
Belgium 9 (66) 1 (11) 2014 2.4–4.9 926 391
Bulgaria 3.1 (15) 6.3 (46) – – 417 677
Czech Republic 5.2 (37) 1 (10) 2014 6.1–6.8 6 610 788
Denmark 55.1 (200) 2 (11) – – –
Germany 18.6 (993) 1.4 (111) – – –
Estonia 113.2 (98) 50.9 (67) 2009 4.3–10.8 2 110 527
Ireland 71.1 (214) 5.4 (25) – – 393 275
Greece – 9.3 (102) 2014 0.6–0.9 368 246
Spain 13 (402) 2.5 (115) 2013 0.2–0.4 2 269 112
France 5.4 (227) 1 (64) – – –
Croatia 20.8 (59) 0 (0) 2012 0.4–0.6 196 150
Italy 8 (313) 2.3 (141) – – –
Cyprus 10 (6) 3.5 (3) 2014 0.4–0.7 382
Latvia 10.6 (14) 37 (74) 2012 7.3–11.7 409 869
Lithuania 44.2 (87) 12.9 (38) – – 154 889
Luxembourg 21.1 (8) 29.1 (16) 2009 4.5–6.9 253 011
Hungary 3.4 (23) 0.1 (1) 2008–09 0.8 460 977
Malta 6.9 (2) 0 (0) – – 314 027
Netherlands 10.8 (119) 0 (0) 2008 0.2–0.2 –
Austria 21.1 (121) 2.5 (21) – – 5 157 666
Poland 8.5 (225) 1 (37) – – 105 890
Portugal 4.5 (31) 3.8 (40) 2012 1.9–2.5 1 677 329
Romania 2.4 (33) 7.7 (154) – – 1 979 259
Slovenia 20 (28) 1 (2) – – 494 890
Slovakia 3.1 (12) 0.2 (1) – – 274 942
Finland 47.4 (166) 1.3 (7) 2012 4.1–6.7 4 522 738
Sweden 92.9 (569) 0.8 (8) 2008–11 1.3 203 847
United 
Kingdom (1)
55.9 (2 332) 2 (131) 2004–11 2.9–3.2 7 199 660
Turkey 9.2 (479) 0.1 (10) – – –
Norway 67.8 (228) 1.4 (7) 2013 2.1–2.9 2 124 180
European Union 19.2 (6 400) 2.4 (1 236) – – –
EU, Turkey and 
Norway
18.3 (7 107) 2.1 (1 253) – – –
Caution is required when comparing drug-induced deaths due to issues of coding, coverage and under-reporting in some countries. 
(1) Syringe data refers to Wales and Scotland (2014) and Northern Ireland (2013).
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Annex I National data tables
SEIZURES
Heroin Cocaine Amphetamines MDMA
Quantity 
seized
Number of 
seizures
Quantity 
seized
Number of 
seizures
Quantity 
seized
Number of 
seizures Quantity seized
Number of 
seizures
Country kg count kg count kg count tablets (kg) count
Belgium 149 2 288 9 293 4 268 208 3 434 44 422 (3) 1 693
Bulgaria 940 137 27 39 216 – 16 845 (148) –
Czech Republic 157 65 5 144 51 1 179 1 338 (0.08) 119
Denmark 13 447 90 2 395 295 1 867 54 690 (–) 688
Germany 780 2 857 1 568 3 395 1 484 13 759 486 852 (–) 3 122
Estonia <0.01 8 3 57 67 319 9 822 (3) 147
Ireland 61 954 66 405 23 75 465 083 (–) 402
Greece 2 528 2 277 297 418 6 64 102 299 (9) 42
Spain 244 6 671 21 685 38 458 839 4 079 559 221 (–) 3 054
France 990 – 6 876 – 321 – 940 389 (–) –
Croatia 47 132 6 231 14 582 – (3) 517
Italy 931 2 123 3 866 4 783 6 184 – (29) 262
Cyprus 0 11 32 107 1 73 17 247 (1.1) 28
Latvia 0.8 229 8 44 15 640 119 (0.3) 15
Lithuania 7 129 116 13 10 130 – (1.9) 16
Luxembourg 7 150 5 169 0.07 9 247 (–) 4
Hungary 70 31 40 143 17 673 13 020 (0.4) 275
Malta 2 33 5 136 0.01 3 334 (–) 31
Netherlands 750 – 10 000 – 681 – 2 442 190 (–) –
Austria 56 428 31 1 078 21 930 5 001 (–) 212
Poland 273 – 31 – 824 – 62 028 (–) –
Portugal 39 690 3 715 1 042 2 77 684 (0.6) 145
Romania 26 218 34 79 4 40 317 966 (0.03) 212
Slovenia 5 289 182 179 22 – 218 (0.1) –
Slovakia 0.1 78 0.02 17 6 672 419 (–) 44
Finland 0.09 113 6 205 298 3 149 131 700 (–) 795
Sweden 24 514 29 142 439 5 286 6 105 (8) 920
United Kingdom 785 10 913 3 562 19 820 1 730 6 725 423 000 (–) 3 913
Turkey 12 756 7 008 393 784 142 403 3 600 831 (–) 3 706
Norway 44 1 294 149 1 101 420 8 145 54 185 (11) 502
European Union 8 883 31 785 61 578 77 767 7 599 43 949 6 101 249 (209) 16 656
EU, Turkey and 
Norway
21 683 40 087 62 120 79 652 8 162 52 497 9 756 265 (219) 20 864
Amphetamines refers to both amphetamine and methamphetamine.
All data are for 2014, except the Netherlands (2012), Finland (numbers of seizures, 2013) and the United Kingdom (2013).
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SEIZURES (continued)
Cannabis resin Herbal cannabis Cannabis plants
Quantity seized Number of seizures Quantity seized
Number of 
seizures Quantity seized
Number of 
seizures
Country kg count kg count plants (kg) count
Belgium 841 5 554 10 744 28 086 356 388 (–) 1 227
Bulgaria 2 14 1 674 3 516 21 516 (–) 100
Czech Republic 15 73 570 2 833 77 685 (–) 484
Denmark 2 211 9 988 58 3 000 11 792 (675) 262
Germany 1 755 5 201 8 515 31 519 132 257 (–) 2 400
Estonia 273 31 352 507 – (13) 30
Ireland 677 258 1 102 1 770 6 309 (–) 340
Greece 36 176 19 568 6 985 14 173 (–) 587
Spain 379 762 174 566 15 174 175 086 270 741 (–) 2 252
France 36 917 – 10 073 – 158 592 (–) –
Croatia 2 371 1 640 5 591 3 602 (–) 188
Italy 113 152 5 303 33 441 8 294 121 659 (–) 1 773
Cyprus 0.1 12 203 901 487 (–) 44
Latvia 30 38 27 366 – (11) 16
Lithuania 841 24 79 341 – (–) –
Luxembourg 1 78 13 1 015 97 (–) 11
Hungary 8 101 529 2 058 3 288 (–) 146
Malta 42 39 70 176 8 (–) 5
Netherlands 2 200 – 12 600 – 1 600 000 (–) –
Austria 101 1 380 1 326 10 088 – (281) 408
Poland 99 – 270 – 95 214 (–) –
Portugal 32 877 3 472 108 555 4 517 (–) 302
Romania 15 154 145 1 967 – (422) 93
Slovenia 2 73 535 3 673 11 067 (–) 212
Slovakia 0.1 12 113 1 061 496 (–) 20
Finland 52 1 467 313 6 167 21 800 (189) 3 409
Sweden 877 6 547 1 041 10 028 – (–) –
United Kingdom 1 134 14 105 18 705 147 309 484 645 (–) 15 744
Turkey 30 635 3 972 92 481 41 594 – (–) 3 017
Norway 1 919 10 509 505 6 534 – (276) 383
European Union 573 921 229 037 139 286 452 892 3 396 333 (1 592) 30 053
EU, Turkey and 
Norway
606 475 243 518 232 271 501 020 3 396 333 (1 868) 33 453
All data are for 2014, except the Netherlands (2012), Finland (numbers of seizures, 2013) and the United Kingdom (2013).
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About this report
The Trends and Developments report presents a 
top-level overview of the drug phenomenon in Europe, 
covering drug supply, use and public health problems 
as well as drug policy and responses. Together with the 
online Statistical Bulletin, Country Overviews and 
Perspectives on Drugs, it makes up the 2016 European 
Drug Report package.
About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For over 20 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
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